Strong on results.

before

Color-enhanced scanning electron micrograph shows *E. coli* 736 culture growing on Adams and Roe agar.

after

E. coli 736 culture after 24-hour incubation with Bactrim (trimethoprim and sulfamethoxazole Roche) at 5×MIC. Note distorted shape of destroyed bacteria.

Simple to take.

ROCHE®

In recurrent urinary tract infections

- **Clears the urinary tract of a wide range of susceptible pathogens**
- **Rapidly relieves symptoms of urgency and dysuria**
- **Destroys potential pathogens that colonize the vaginal area**

Bactericidal against *E. coli* and other uropathogens *in vitro*

Bactrim demonstrates bactericidal action against major uropathogens *in vitro*. *E. coli, Klebsiella pneumoniae* and *Enterobacter* were all rapidly destroyed by Bactrim at 5× MIC levels—and these levels are usually greatly exceeded in the urine after a standard dosage of Bactrim DS.[1] However, *in vitro* activity does not necessarily correlate with clinical results.

Unsurpassed efficacy in clinical practice

In chronic or recurrent urinary tract infections, Bactrim is highly effective[2] and has been repeatedly recommended for its strong results,[3] its site-to-source action (in urinary tract, vagina and bowel)[4] and its ability to penetrate the renal parenchyma in chronic pyelonephritis.[5] Clinicians often prefer Bactrim as treatment for the entire course of therapy when the organism is known to be susceptible,[6] and as first-line therapy in recurrent urinary tract infections.[7]

Effective and economical *b.i.d.* therapy

Just one Bactrim DS tablet *b.i.d.* for 10 to 14 days provides effective, economical therapy for recurrent urinary tract infections.

Bactrim is indicated for the treatment of recurrent urinary tract infections due to susceptible strains of *E. coli, Klebsiella-Enterobacter, Proteus mirabilis, Proteus vulgaris* and *Proteus morganii.* However, it is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single antimicrobial agent rather than the combination.

Maintain adequate fluid intake during therapy. Bactrim is contraindicated in pregnancy at term, during lactation, in infants under two months of age and in documented megaloblastic anemia due to folate deficiency.

Bactrim™ DS

(trimethoprim and sulfamethoxazole/Roche)

B.I.D. for enhanced compliance.

Please see summary of product information *on the following page.*

References: 1. Data on file, Hoffmann-La Roche Inc., Nutley, NJ. 2. Wormser GP, Keusch GT, Heel RC: *Drugs 24*:459-518, Dec 1982. 3. Ronald AR: *Clin Ther 3*:176-189, 1980. 4. Rubin RH, Swartz MN: *N Engl J Med 303*:426-432, Aug 21, 1980. 5. Cunha BA: *Postgrad Med 70*(6):149-156, Dec 1981. 6. Neu HC: *Infectious Diseases 10*(6):4, 19, Jun 1980. 7. Jones SR: *Ration Drug Ther 13*(11) 1-5, Nov 1979.

Dedication

Essential for a physician, essential for a malpractice insurance company

At NORCAL we are dedicated to serving the malpractice insurance needs of our physician members. We provide the service and protection you should expect from a mutual insurance company owned and directed by its physician members. We are dedicated to:

- Realistically priced protection
- A comprehensive loss prevention program
- Professional claims experts
- Management performance and financial stability

At NORCAL, medical malpractice insurance is our only business.

Find out more about NORCAL today. Phone toll-free (800) 652-1051.

NORCAL
Medical Malpractice Insurance

NORCAL Mutual Insurance Company
333 Market St., San Francisco, CA 94105
(800) 652-1051 or (415) 777-4200

Endorsed by more California Medical Societies

One for Step-1

CORGARD® TABLETS
Nadolol Tablets

DESCRIPTION: Corgard (nadolol) is a synthetic nonselective beta-adrenergic receptor blocking agent.

CONTRAINDICATIONS: Bronchial asthma, sinus bradycardia and greater than first degree conduction block, cardiogenic shock, and overt cardiac failure (see WARNINGS).

WARNINGS: Cardiac Failure — Sympathetic stimulation may be a vital component supporting circulatory function in congestive heart failure, and its inhibition by beta-blockade may precipitate more severe failure. Although beta-blockers should be avoided in overt congestive heart failure, if necessary, they can be used with caution in patients with a history of failure who are well-compensated, usually with digitalis and diuretics. Beta-adrenergic blocking agents do not abolish the inotropic action of digitalis on heart muscle. IN PATIENTS WITHOUT A HISTORY OF HEART FAILURE, continued use of beta-blockers can, in some cases, lead to cardiac failure; therefore, at first sign or symptom of heart failure, digitalize and/or give diuretics, and closely observe response, or discontinue nadolol (gradually if possible).

Exacerbation of Ischemic Heart Disease Following Abrupt Withdrawal — Hypersensitivity to catecholamines has been observed in patients withdrawn from beta-blocker therapy; exacerbation of angina and, in some cases, myocardial infarction have occurred after *abrupt* discontinuation of such therapy. When discontinuing chronic use of nadolol, particularly in patients with ischemic heart disease, gradually reduce dosage over a 1- to 2-week period and carefully monitor the patient. Reinstitute nadolol promptly (at least temporarily) and take other measures appropriate for management of unstable angina if angina markedly worsens or acute coronary insufficiency develops. Warn patients not to interrupt or discontinue therapy without physician's advice. Because coronary artery disease is common and may be unrecognized, it may be prudent not to discontinue nadolol therapy abruptly even in patients treated only for hypertension.

Nonallergic Bronchospasm (e.g., chronic bronchitis, emphysema) — PATIENTS WITH BRONCHOSPASTIC DISEASES SHOULD IN GENERAL NOT RECEIVE BETA-BLOCKERS. Administer nadolol with caution since it may block bronchodilation produced by endogenous or exogenous catecholamine stimulation of $beta_2$ receptors.

Major Surgery — Because beta blockade impairs the ability of the heart to respond to reflex stimuli and may increase risks of general anesthesia and surgical procedures, resulting in protracted hypotension or low cardiac output, it has generally been suggested that such therapy should be withdrawn several days prior to surgery. Recognition of the increased sensitivity to catecholamines of patients recently withdrawn from beta-blocker therapy, however, has made this recommendation controversial. If possible, withdraw beta-blockers well before surgery takes place. In emergency surgery, inform the anesthesiologist that the patient is on beta-blocker therapy. Use of beta-receptor agonists such as isoproterenol, dopamine, dobutamine, or levarterenol can reverse the effects of nadolol. Difficulty in restarting and maintaining the heart beat has also been reported with beta-adrenergic receptor blocking agents.

Diabetes and Hypoglycemia — Beta-adrenergic blockade may prevent the appearance of premonitory signs and symptoms (e.g., tachycardia and blood pressure changes) of acute hypoglycemia. This is especially important with labile diabetics. Beta-blockade also reduces release of insulin in response to hyperglycemia; therefore, it may be necessary to adjust dose of antidiabetic drugs.

Thyrotoxicosis — Beta-adrenergic blockade may mask certain clinical signs (e.g., tachycardia) of hyperthyroidism. To avoid abrupt withdrawal of beta-adrenergic blockade which might precipitate a thyroid storm, carefully manage patients suspected of developing thyrotoxicosis.

PRECAUTIONS: Impaired Hepatic or Renal Function — Use nadolol with caution in presence of either of these conditions (see DOSAGE AND ADMINISTRATION section of package insert).

Information for Patients — Warn patients, especially those with evidence of coronary artery insufficiency, against interruption or discontinuation of nadolol without physician's advice. Although cardiac failure rarely occurs in properly selected patients, advise patients being treated with beta-adrenergic blocking agents to consult physician at first sign or symptom of impending failure.

Drug Interactions — Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents. When treating patients with nadolol plus a catecholamine-depleting agent, carefully observe for evidence of hypotension and/or excessive bradycardia which may produce vertigo, syncope, or postural hypotension.

Carcinogenesis, Mutagenesis, Impairment of Fertility — In 1 to 2 years' oral toxicologic studies in mice, rats, and dogs, nadolol did not produce significant toxic effects. In 2-year oral carcinogenic studies in rats and mice, nadolol did not produce neoplastic, preneoplastic, or nonneoplastic pathologic lesions.

Pregnancy — In animal reproduction studies with nadolol, evidence of embryo- and fetotoxicity was found in rabbits (but not in rats or hamsters) at doses 5 to 10 times greater (on a mg/kg basis) than maximum indicated human dose; no teratogenic potential was seen in any of these species. There are no well-controlled studies in pregnant women; therefore, use nadolol in pregnant women only if potential benefit justifies potential risk to the fetus.

Nursing Mothers — It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, exercise caution when nadolol is administered to a nursing woman. Animal studies showed that nadolol is found in the milk of lactating rats.

Pediatric Use — Safety and effectiveness in children have not been established.

ADVERSE REACTIONS: Most adverse effects have been mild and transient and have rarely required nadolol withdrawal.

Cardiovascular — Bradycardia with heart rates of less than 60 beats per minute occurs commonly, and heart rates below 40 beats per minute and/or symptomatic bradycardia were seen in about 2 of 100 patients. Symptoms of peripheral vascular insufficiency, usually of the Raynaud type, have occurred in approximately 2 of 100 patients. Cardiac failure, hypotension, and rhythm/conduction disturbances have each occurred in about 1 of 100 patients. Single instances of first degree and third degree heart block have been reported; intensification of AV block is a known effect of beta-blockers (see also CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS). **Central Nervous System** — Dizziness or fatigue reported in approximately 2 of 100 patients; paresthesias, sedation, and change in behavior reported in approximately 6 of 1000 patients. **Respiratory** — Bronchospasm reported in approximately 1 of 1000 patients (see CONTRAINDICATIONS and WARNINGS). **Gastrointestinal** — Nausea, diarrhea, abdominal discomfort, constipation, vomiting, indigestion, anorexia, bloating, and flatulence each reported in 1 to 5 of 1000 patients. **Miscellaneous** — Each of the following reported in 1 to 5 of 1000 patients: rash; pruritus; headache; dry mouth, eyes, or skin; impotence or decreased libido; facial swelling; weight gain; slurred speech; cough; nasal stuffiness; sweating; tinnitus; blurred vision. Although relationship to drug usage is not clear, sleep disturbances have been reported. The oculomucocutaneous syndrome associated with practolol has not been reported with nadolol.

Potential Adverse Effects: Although other adverse effects reported with other beta-adrenergic blocking agents have not been reported with nadolol, they should be considered potential adverse effects of nadolol. **Central Nervous System** — reversible mental depression progressing to catatonia; visual disturbances; hallucinations; an acute reversible syndrome characterized by disorientation for time and place; short-term memory loss, emotional lability with slightly clouded sensorium; decreased performance on neuropsychometrics. **Gastrointestinal** — mesenteric arterial thrombosis; ischemic colitis. **Hematologic** — agranulocytosis; thrombocytopenic or nonthrombocytopenic purpura. **Allergic** — fever combined with aching and sore throat; laryngospasm; respiratory distress. **Miscellaneous** — reversible alopecia; Peyronie's disease; erythematous rash.

OVERDOSAGE: Nadolol can be removed from the general circulation by hemodialysis. In addition to gastric lavage, employ the following measures as appropriate. In determining duration of corrective therapy, take note of long duration of effect of nadolol.

Excessive Bradycardia — Administer atropine (0.25 to 1.0 mg). If there is no response to vagal blockade, administer isoproterenol cautiously.

Cardiac Failure — Administer a digitalis glycoside and diuretic. It has been reported that glucagon may also be useful in this situation.

Hypotension — Administer vasopressors, e.g., epinephrine or levarterenol. (There is evidence that epinephrine may be the drug of choice.)

Bronchospasm — Administer a $beta_2$-stimulating agent and/or a theophylline derivative.

DOSAGE: For all patients, DOSAGE MUST BE INDIVIDUALIZED.

For **angina pectoris,** usual initial dose is 40 mg q.d.; gradually increase in 40 to 80 mg increments at 3 to 7 day intervals until optimum clinical response or pronounced slowing of the heart rate; usual maintenance dose is 80 to 240 mg q.d. (most patients respond to 160 mg or less daily). If treatment is to be discontinued, reduce dosage gradually over a period of 1 to 2 weeks (see WARNINGS).

For **hypertension,** usual initial dose is 40 mg q.d.; gradually increase in 40 to 80 mg increments until optimum blood pressure reduction is achieved; usual maintenance dose is 80 to 320 mg q.d. (rarely, doses up to 640 mg may be needed).

Patients with renal failure require adjustment in dosing interval; see package insert for dosage in these patients.

For full prescribing information, consult package insert.

HOW SUPPLIED: In scored tablets containing 40, 80, 120, or 160 mg nadolol per tablet in bottles of 100 and 1000 tablets and in Unimatic® unit-dose packs of 100 tablets.

SQUIBB®
Innovators in cardiovascular medicine

514-524 Issued: May 1984

Once-a-day

CORGARD® STEP-1 nadolol tablets

ANNOUNCING A NEW BEGINNING...

Beta-blockers now advocated by The Joint National Committee for broad Step-1 usage

In a report issued on May 4, 1984, the Joint National Committee recommended the following approach to Step-1 Therapy:

Begin with a thiazide-type diuretic OR a beta-blocker.[1]

ANNOUNCING AN EASY WAY TO BEGIN...

CORGARD® (nadolol tablets) Step-1 Starter Kits now available

To help you initiate therapy with once-a-day CORGARD, special Patient Starter Kits have been designed. Each kit contains a handy sodium content wallchart for you plus these tools for your patients:

- A three-week regimen of CORGARD
- A hypertension education booklet
- An instruction sheet of basic do's and don'ts... with a space provided for your special instructions
- The opportunity to select a paperback book on a topic relevant to control of high blood pressure

Watch your mail or see your Squibb Representative for complete details on ordering your first 10 CORGARD Starter Kits. Physicians desiring CORGARD Patient Starter Kits may order them directly by sending a request on their letterhead to:
E.R. Squibb & Sons, Inc., Sample Fulfillment Division, P.O. Box 9513, Philadelphia, PA 19124
Please allow 4-6 weeks for delivery.

Reference: 1. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure: 1984 Report. Arch Intern Med 144(5): 1045-1057, 1984.

Please see adjacent page of this advertisement for brief summary.

CPS & IBM®

your "Olympic" Medical Billing Team



Names you know you can trust. Bringing together the best in medical billing and hardware, CPS now offers its **Son-Of-A-Batch™** System on the IBM-PC. Combining the best aspects of the microcomputer and the CPS System, you now have the "Best of Both Worlds"....

While you complete your Word Processing, Accounts Payable and Payroll in-house, CPS will do the time consuming "crunch work" including, but not limited to:

- **Printing all Insurance Forms, including MediCal**
- **Electronic Billing for MediCare, etc.**
- **Prepare and Mail all Private Patient Statements**
- **A/R Reports, with 30-60-90-120 Day Aging**
- **Past Due Collection System**
- **Complete Recall System**
- **Month-End Financial Reports by Doctor and/or Group**

and, the ENTIRE Billing System is only 55¢/month for each active account.

THE PRICE IS RIGHT, THE TIME IS NOW!

Join the "Olympic" Medical Billing Team in the race for Practice Profitability

Call or Write Today

MEDICAL BILLING SYSTEMS

Bay Area
115 Sansome St., #812
San Francisco, CA 94104
(415) 986-8300

or call 1-800-634-4500

Offices in
Los Angeles • San Diego • Newport Beach

Send information on the CPS "Olympic" Billing System...

NAME: _____

ADDRESS: _____

CITY: _____ STATE: _____ ZIP: _____

TELEPHONE: (_____) _____

CONTACT: _____

IBM® is a Registered Trademark of International Business Machines Corporation.



Only Burroughs Wellcome Co. gives you

ZYLOPRIM®
(allopurinol)



and a whole lot more!

Full support for you, the physician:

- Continuing medical education materials
- On-going clinical studies
- Physician consultation readily available for your questions concerning Zyloprim
- A choice of 100 mg and 300 mg scored tablets

Full support for your patients:

- Patient starter/conversion kits for easy titration of initial dosage
- Patient education pamphlets to encourage compliance
- Burroughs Wellcome Co. quality and economy

Wellcome

Burroughs Wellcome Co.
Research Triangle Park
North Carolina 27709

THE PROFESSIONALS IN PROFESSIONAL LIABILITY INSURANCE. THE DOCTORS' COMPANY.

THE PROFESSIONALS FOR THE MEDICAL PROFESSION. THE DOCTORS' LIFE INSURANCE COMPANY.



THE DOCTORS' COMPANY
AN INTERINSURANCE EXCHANGE
THE DOCTORS' LIFE INSURANCE COMPANY
A WHOLLY-OWNED SUBSIDIARY OF THE DOCTORS COMPANY

401 WILSHIRE BLVD., SANTA MONICA, CA 90401
(213) 451-3011
TOLL FREE, (800) 352-7271 (CALIFORNIA);
(800) 421-2368 (OTHER STATES)

SERVING THE INSURANCE NEEDS OF PHYSICIANS IN CALIFORNIA/NEVADA/ WYOMING/MONTANA

Halcion® 0.25 mg Tablets
triazolam Ⓒ IV



Upjohn Please see next page for brief summary of prescribing information.

Better Initiation and Maintenance of Sleep

Better Morning and Daytime Alertness

RAPIDLY ABSORBED FOR IMPROVED SLEEP

PROMPTLY EXCRETED FOR DAYTIME ALERTNESS

Halcion
triazolam (IV)

0.25 mg Tablets
Initiate at 0.125 mg

Halcion Tablets
triazolam (IV)



Special Dosage Guidelines for Geriatric Patients

0.125 MG TO 0.25 MG
Initiate at 0.125 mg (half of a 0.25 mg scored tablet) until individual response is determined.

Because geriatric and/or debilitated patients respond favorably to lower doses of *Halcion*, initiation at the above dosage is recommended.

DOSAGE FOR NON-GERIATRIC PATIENTS: 0.25 MG TO 0.5 MG

Patients should be advised against engaging in hazardous tasks that require mental alertness (operating machinery or driving a motor vehicle).

Reference: 1. Ogura C, et al: Residual effects of hypnotics: Triazolam, flurazepam, and nitrazepam. *Psychopharmacol* 1980; 68:61-65.

Halcion Tablets
triazolam (IV)

INDICATIONS AND USAGE
HALCION Tablets are indicated in the short-term management of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings.

It is recommended that HALCION not be prescribed in quantities exceeding a one-month supply.

CONTRAINDICATIONS
Patients with known hypersensitivity to this drug or other benzodiazepines.

HALCION is contraindicated in pregnant women due to potential fetal damage. Patients likely to become pregnant while receiving HALCION should be warned of the potential risk to the fetus.

WARNINGS
Overdosage may occur at 2 mg, four times the maximum recommended therapeutic dose (0.5 mg). Patients should be cautioned not to exceed prescribed dosage.

Because of its depressant CNS effects, patients should be cautioned against engaging in hazardous occupations requiring complete mental alertness and also about the simultaneous ingestion of alcohol and other CNS depressant drugs.

Anterograde amnesia and paradoxical reactions have been reported with HALCION and some other benzodiazepines.

PRECAUTIONS
General: In elderly and/or debilitated patients, treatment should be initiated at 0.125 mg to decrease the possibility of development of oversedation, dizziness, or impaired coordination. Caution should be exercised in patients with signs or symptoms of depression which could be intensified by hypnotic drugs. Suicidal tendencies and intentional overdosage is more common in these patients. The usual precautions should be observed in patients with impaired renal or hepatic function and chronic pulmonary insufficiency. Information for Patients: Alert patients about: (a) consumption of alcohol and drugs, (b) possible fetal abnormalities, (c) operating machinery or driving, (d) not increasing dose of the drug due to risk of dependence, (e) possible worsening of sleep after discontinuing HALCION. Laboratory Tests: Not ordinarily required in otherwise healthy patients. Drug Interactions: Additive CNS depressant effects with other psychotropics, anticonvulsants, antihistaminics, ethanol, and other CNS depressants. Pharmacokinetic interactions of benzodiazepines with other drugs have been reported. Carcinogenesis, Mutagenesis, Impairment of Fertility: No evidence of carcinogenic potential was observed in mice during a 24-month study with HALCION in doses up to 4000 times the human dose. Pregnancy: Benzodiazepines may cause fetal damage if administered during pregnancy. The child born of a mother who is on benzodiazepines may be at some risk for withdrawal symptoms and neonatal flaccidity during the postnatal period. Nursing Mothers: Administration to nursing mothers is not recommended. Pediatric Use: Safety and efficacy in children below the age of 18 have not been established.

ADVERSE REACTIONS
During placebo-controlled clinical studies in which 1003 patients received HALCION Tablets, the most troublesome side effects were extensions of the pharmacologic activity of HALCION, e.g. drowsiness, dizziness, or lightheadedness.

	HALCION	Placebo
Number of Patients	1003	997
% of Patients Reporting:		
Central Nervous System		
Drowsiness	14.0	6.4
Headache	9.7	8.4
Dizziness	7.8	3.1
Nervousness	5.2	4.5
Lightheadedness	4.9	0.9
Coordination Disorder/Ataxia	4.6	0.8
Gastrointestinal		
Nausea/Vomiting	4.6	3.7

In addition, the following adverse events have been reported less frequently (i.e., 0.9-0.5%): euphoria, tachycardia, tiredness, confusional states/memory impairment, cramps/pain, depression, visual disturbances.

Rare (i.e., less than 0.5%) adverse reactions included constipation, taste alterations, diarrhea, dry mouth, dermatitis/allergy, dreaming/nightmares, insomnia, paresthesia, tinnitus, dysesthesia, weakness, congestion, death from hepatic failure in a patient also receiving diuretic drugs.

The following adverse events have been reported in association with the use of benzodiazepines: dystonia, irritability, anorexia, fatigue, sedation, slurred speech, jaundice, pruritus, dysarthria, changes in libido, menstrual irregularities, incontinence and urinary retention.

As with all benzodiazepines, paradoxical reactions such as stimulation, agitation, increased muscle spasticity, sleep disturbances, hallucinations and other adverse behavioral effects may occur rarely and in a random fashion. Should these occur, use of the drug should be discontinued.

No laboratory changes were considered to be of physiological significance.

When treatment is protracted, periodic blood counts, urinalysis and blood chemistry analyses are advisable.

Minor changes in EEG patterns, usually low-voltage fast activity have been observed in patients during HALCION therapy and are of no known significance.

DRUG ABUSE AND DEPENDENCE
Controlled Substance: HALCION Tablets are a Controlled Substance in Schedule IV. Abuse and Dependence: Withdrawal symptoms have occurred following abrupt discontinuance of benzodiazepines. Patients with a history of seizures are at particular risk. Addiction-prone patients should be closely monitored. Repeat prescriptions should be limited to those under medical supervision.

OVERDOSAGE
Because of the potency of triazolam, overdosage may occur at 2 mg, four times the maximum recommended therapeutic dose (0.5 mg). Manifestations of overdosage include somnolence, confusion, impaired coordination, slurred speech, and ultimately, coma. Respiration, pulse, and blood pressure should be monitored and supported by general measures when necessary. Immediate gastric lavage should be performed. Multiple agents may have been ingested.

Store at controlled room temperature 15°-30°C (59°-86°F).

Caution: Federal law prohibits dispensing without prescription.

J-3671R October 1983

Upjohn THE UPJOHN COMPANY
Kalamazoo, Michigan 49001 USA

BALANCED CALCIUM CHANNEL BLOCKADE!

Low incidence of side effects
CARDIZEM® (diltiazem HCl) produces an incidence of adverse reactions not greater than that reported with placebo therapy, thus contributing to the patient's sense of well-being.

Reduces angina attack frequency*
42% to 46% decrease reported in multicenter study.[1]

Increases exercise tolerance*
In Bruce exercise test,[2] control patients averaged 8.0 minutes to onset of pain; Cardizem patients averaged 9.8 minutes ($P<.005$).

*Cardizem is indicated in the treatment of angina pectoris due to coronary artery spasm and in the management of chronic stable angina (classic effort-associated angina) in patients who cannot tolerate therapy with beta-blockers and/or nitrates or who remain symptomatic despite adequate doses of these agents.

References:
1. Strauss WE, McIntyre KM, Parisi AF, et al: Safety and efficacy of diltiazem hydrochloride for the treatment of stable angina pectoris: Report of a cooperative clinical trial. Am J Cardiol 49:660-666, 1982.
2. Pool PE, Seagren SC, Bonanno JA, et al: The treatment of exercise-inducible chronic stable angina with diltiazem: Effect on treadmill exercise. Chest 78 (July suppl):234-238, 1980.

CARDIZEM®
(diltiazem HCl)

THE BALANCED CALCIUM CHANNEL BLOCKER

Please see full prescribing information on following page.

2/84

PROFESSIONAL USE INFORMATION

cardizem®
(diltiazem HCl)
30 mg and 60 mg tablets

DESCRIPTION

CARDIZEM® (diltiazem hydrochloride) is a calcium ion influx inhibitor (slow channel blocker or calcium antagonist). Chemically, diltiazem hydrochloride is 1,5-Benzothiazepin-4(5H)one,3-(acetyloxy) -5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-, monohydrochloride,(+) -cis-. The chemical structure is:



Diltiazem hydrochloride is a white to off-white crystalline powder with a bitter taste. It is soluble in water, methanol, and chloroform. It has a molecular weight of 450.98. Each tablet of CARDIZEM contains either 30 mg or 60 mg diltiazem hydrochloride for oral administration.

CLINICAL PHARMACOLOGY

The therapeutic benefits achieved with CARDIZEM are believed to be related to its ability to inhibit the influx of calcium ions during membrane depolarization of cardiac and vascular smooth muscle.

Mechanisms of Action. Although precise mechanisms of its antianginal actions are still being delineated, CARDIZEM is believed to act in the following ways:

1. Angina Due to Coronary Artery Spasm: CARDIZEM has been shown to be a potent dilator of coronary arteries both epicardial and subendocardial. Spontaneous and ergonovine-induced coronary artery spasm are inhibited by CARDIZEM.
2. Exertional Angina: CARDIZEM has been shown to produce increases in exercise tolerance, probably due to its ability to reduce myocardial oxygen demand. This is accomplished via reductions in heart rate and systemic blood pressure at submaximal and maximal exercise work loads.

In animal models, diltiazem interferes with the slow inward (depolarizing) current in excitable tissue. It causes excitation-contraction uncoupling in various myocardial tissues without changes in the configuration of the action potential. Diltiazem produces relaxation of coronary vascular smooth muscle and dilation of both large and small coronary arteries at drug levels which cause little or no negative inotropic effect. The resultant increases in coronary blood flow (epicardial and subendocardial) occur in ischemic and nonischemic models and are accompanied by dose-dependent decreases in systemic blood pressure and decreases in peripheral resistance.

Hemodynamic and Electrophysiologic Effects. Like other calcium antagonists, diltiazem decreases sinoatrial and atrioventricular conduction in isolated tissues and has a negative inotropic effect in isolated preparations. In the intact animal, prolongation of the AH interval can be seen at higher doses.

In man, diltiazem prevents spontaneous and ergonovine-provoked coronary artery spasm. It causes a decrease in peripheral vascular resistance and a modest fall in blood pressure and, in exercise tolerance studies in patients with ischemic heart disease, reduces the heart rate-blood pressure product for any given work load. Studies to date, primarily in patients with good ventricular function, have not revealed evidence of a negative inotropic effect; cardiac output, ejection fraction, and left ventricular end diastolic pressure have not been affected. There are as yet few data on the interaction of diltiazem and beta-blockers. Resting heart rate is usually unchanged or slightly reduced by diltiazem.

Intravenous diltiazem in doses of 20 mg prolongs AH conduction time and AV node functional and effective refractory periods approximately 20%. In a study involving single oral doses of 300 mg of CARDIZEM in six normal volunteers, the average maximum PR prolongation was 14% with no instances of greater than first-degree AV block. Diltiazem-associated prolongation of the AH interval is not more pronounced in patients with first-degree heart block. In patients with sick sinus syndrome, diltiazem significantly prolongs sinus cycle length (up to 50% in some cases).

Chronic oral administration of CARDIZEM in doses of up to 240 mg/day has resulted in small increases in PR interval, but has not usually produced abnormal prolongation. There were, however, three instances of second-degree AV block and one instance of third-degree AV block in a group of 959 chronically treated patients.

Pharmacokinetics and Metabolism. Diltiazem is absorbed from the tablet formulation to about 80% of a reference capsule and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous dosing) of about 40%. CARDIZEM undergoes extensive hepatic metabolism in which 2% to 4% of the unchanged drug appears in the urine. In vitro binding studies show CARDIZEM is 70% to 80% bound to plasma proteins. Competitive ligand binding studies have also shown CARDIZEM binding is not altered by therapeutic concentrations of digoxin, hydrochlorothiazide, phenylbutazone, propranolol, salicylic acid, or warfarin. Single oral doses of 30 to 120 mg of CARDIZEM result in detectable plasma levels within 30 to 60 minutes and peak plasma levels two to three hours after drug administration. The plasma elimination half-life following single or multiple drug administration is approximately 3.5 hours. Desacetyl diltiazem is also present in the plasma at levels of 10% to 20% of the parent drug and is 25% to 50% as potent a coronary vasodilator as diltiazem. Therapeutic blood levels of CARDIZEM appear to be in the range of 50 to 200 ng/ml. There is a departure from dose-linearity when single doses above 60 mg are given; a 120-mg dose gave blood levels three times that of the 60-mg dose. There is no information about the effect of renal or hepatic impairment on excretion or metabolism of diltiazem.

INDICATIONS AND USAGE

1. **Angina Pectoris Due to Coronary Artery Spasm.** CARDIZEM is indicated in the treatment of angina pectoris due to coronary artery spasm. CARDIZEM has been shown effective in the treatment of spontaneous coronary artery spasm presenting as Prinzmetal's variant angina (resting angina with ST-segment elevation occurring during attacks).
2. **Chronic Stable Angina (Classic Effort-Associated Angina).** CARDIZEM is indicated in the management of chronic stable angina. CARDIZEM has been effective in controlled trials in reducing angina frequency and increasing exercise tolerance.

There are no controlled studies of the effectiveness of the concomitant use of diltiazem and beta-blockers or of the safety of this combination in patients with impaired ventricular function or conduction abnormalities.

CONTRAINDICATIONS

CARDIZEM is contraindicated in (1) patients with sick sinus syndrome except in the presence of a functioning ventricular pacemaker, (2) patients with second- or third-degree AV block except in the presence of a functioning ventricular pacemaker, and (3) patients with hypotension (less than 90 mm Hg systolic).

WARNINGS

1. **Cardiac Conduction.** CARDIZEM prolongs AV node refractory periods without significantly prolonging sinus node recovery time, except in patients with sick sinus syndrome. This effect may rarely result in abnormally slow heart rates (particularly in patients with sick sinus syndrome) or second- or third-degree AV block (six of 1243 patients for 0.48%). Concomitant use of diltiazem with beta-blockers or digitalis may result in additive effects on cardiac conduction. A patient with Prinzmetal's angina developed periods of asystole (2 to 5 seconds) after a single dose of 60 mg of diltiazem.
2. **Congestive Heart Failure.** Although diltiazem has a negative inotropic effect in isolated animal tissue preparations, hemodynamic studies in humans with normal ventricular function have not shown a reduction in cardiac index nor consistent negative effects on contractility (dp/dt). Experience with the use of CARDIZEM alone or in combination with beta-blockers in patients with impaired ventricular function is very limited. Caution should be exercised when using the drug in such patients.
3. **Hypotension.** Decreases in blood pressure associated with CARDIZEM therapy may occasionally result in symptomatic hypotension.
4. **Acute Hepatic Injury.** In rare instances, patients receiving CARDIZEM have exhibited reversible acute hepatic injury as evidenced by moderate to extreme elevations of liver enzymes. (See PRECAUTIONS and ADVERSE REACTIONS.)

PRECAUTIONS

General. CARDIZEM (diltiazem hydrochloride) is extensively metabolized by the liver and excreted by the kidneys and in bile. As with any new drug given over prolonged periods, laboratory parameters should be monitored at regular intervals. The drug should be used with caution in patients with impaired renal or hepatic function. In subacute and chronic dog and rat studies designed to produce toxicity, high doses of diltiazem were associated with hepatic damage. In special subacute hepatic studies, oral doses of 125 mg/kg and higher in rats were associated with histological changes in the liver which were reversible when the drug was discontinued. In dogs, doses of 20 mg/kg were also associated with hepatic changes; however, these changes were reversible with continued dosing.

Drug Interaction. Pharmacologic studies indicate that there may be additive effects in prolonging AV conduction when using beta-blockers or digitalis concomitantly with CARDIZEM. (See WARNINGS).

Controlled and uncontrolled domestic studies suggest that concomitant use of CARDIZEM and beta-blockers or digitalis is usually well tolerated. Available data are not sufficient, however, to predict the effects of concomitant treatment, particularly in patients with left ventricular dysfunction or cardiac conduction abnormalities. In healthy volunteers, diltiazem has been shown to increase serum digoxin levels up to 20%.

Carcinogenesis, Mutagenesis, Impairment of Fertility. A 24-month study in rats and a 21-month study in mice showed no evidence of carcinogenicity. There was also no mutagenic response in in vitro bacterial tests. No intrinsic effect on fertility was observed in rats.

Pregnancy. Category C. Reproduction studies have been conducted in mice, rats, and rabbits. Administration of doses ranging from five to ten times greater (on a mg/kg basis) than the daily recommended therapeutic dose has resulted in embryo and fetal lethality. These doses, in some studies, have been reported to cause skeletal abnormalities. In the perinatal/postnatal studies, there was some reduction in early individual pup weights and survival rates. There was an increased incidence of stillbirths at doses of 20 times the human dose or greater.

There are no well-controlled studies in pregnant women; therefore, use CARDIZEM in pregnant women only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, exercise caution when CARDIZEM is administered to a nursing woman if the drug's benefits are thought to outweigh its potential risks in this situation.

Pediatric Use. Safety and effectiveness in children have not been established.

ADVERSE REACTIONS

Serious adverse reactions have been rare in studies carried out to date, but it should be recognized that patients with impaired ventricular function and cardiac conduction abnormalities have usually been excluded.

In domestic placebo-controlled trials, the incidence of adverse reactions reported during CARDIZEM therapy was not greater than that reported during placebo therapy.

The following represent occurrences observed in clinical studies which can be at least reasonably associated with the pharmacology of calcium influx inhibition. In many cases, the relationship to CARDIZEM has not been established. The most common occurrences, as well as their frequency of presentation, are: edema (2.4%), headache (2.1%), nausea (1.9%), dizziness (1.5%), rash (1.3%), asthenia (1.2%), AV block (1.1%). In addition, the following events were reported infrequently (less than 1%) with the order of presentation corresponding to the relative frequency of occurrence.

Cardiovascular:	Flushing, arrhythmia, hypotension, bradycardia, palpitations, congestive heart failure, syncope.
Nervous System:	Paresthesia, nervousness, somnolence, tremor, insomnia, hallucinations, and amnesia.
Gastrointestinal:	Constipation, dyspepsia, diarrhea, vomiting, mild elevations of alkaline phosphatase, SGOT, SGPT, and LDH.
Dermatologic:	Pruritus, petechiae, urticaria, photosensitivity.
Other:	Polyuria, nocturia.

The following additional experiences have been noted:

A patient with Prinzmetal's angina experiencing episodes of vasospastic angina developed periods of transient asymptomatic asystole approximately five hours after receiving a single 60-mg dose of CARDIZEM.

The following postmarketing events have been reported infrequently in patients receiving CARDIZEM: erythema multiforme; leukopenia; and extreme elevations of alkaline phosphatase, SGOT, SGPT, LDH, and CPK. However, a definitive cause and effect between these events and CARDIZEM therapy is yet to be established.

OVERDOSAGE OR EXAGGERATED RESPONSE

Overdosage experience with oral diltiazem has been limited. Single oral doses of 300 mg of CARDIZEM have been well tolerated by healthy volunteers. In the event of overdosage or exaggerated response, appropriate supportive measures should be employed in addition to gastric lavage. The following measures may be considered:

Bradycardia	Administer atropine (0.60 to 1.0 mg). If there is no response to vagal blockade, administer isoproterenol cautiously.
High-Degree AV Block	Treat as for bradycardia above. Fixed high-degree AV block should be treated with cardiac pacing.
Cardiac Failure	Administer inotropic agents (isoproterenol, dopamine, or dobutamine) and diuretics.
Hypotension	Vasopressors (eg, dopamine or levarterenol bitartrate).

Actual treatment and dosage should depend on the severity of the clinical situation and the judgment and experience of the treating physician.

The oral/LD_{50}'s in mice and rats range from 415 to 740 mg/kg and from 560 to 810 mg/kg, respectively. The intravenous LD_{50}'s in these species were 60 and 38 mg/kg, respectively. The oral LD_{50} in dogs is considered to be in excess of 50 mg/kg, while lethality was seen in monkeys at 360 mg/kg. The toxic dose in man is not known, but blood levels in excess of 800 ng/ml have not been associated with toxicity.

DOSAGE AND ADMINISTRATION

Exertional Angina Pectoris Due to Atherosclerotic Coronary Artery Disease or Angina Pectoris at Rest Due to Coronary Artery Spasm. Dosage must be adjusted to each patient's needs. Starting with 30 mg four times daily, before meals and at bedtime, dosage should be increased gradually (given in divided doses three or four times daily) at one- to two-day intervals until optimum response is obtained. Although individual patients may respond to any dosage level, the average optimum dosage range appears to be 180 to 240 mg/day. There are no available data concerning dosage requirements in patients with impaired renal or hepatic function. If the drug must be used in such patients, titration should be carried out with particular caution.

Concomitant Use With Other Antianginal Agents:

1. **Sublingual NTG** may be taken as required to abort acute anginal attacks during CARDIZEM therapy.
2. **Prophylactic Nitrate Therapy**—CARDIZEM may be safely coadministered with short- and long-acting nitrates, but there have been no controlled studies to evaluate the antianginal effectiveness of this combination.
3. **Beta-blockers.** (See WARNINGS and PRECAUTIONS.)

HOW SUPPLIED

Cardizem 30-mg tablets are supplied in bottles of 100 (NDC 0088-1771-47) and in Unit Dose Identification Paks of 100 (NDC 0088-1771-49). Each green tablet is engraved with MARION on one side and 1771 engraved on the other. CARDIZEM 60-mg scored tablets are supplied in bottles of 100 (NDC 0088-1772-47) and in Unit Dose Identification Paks of 100 (NDC 0088-1772-49). Each yellow tablet is engraved with MARION on one side and 1772 on the other.

Issued 4/1/84

Another patient benefit product from

PHARMACEUTICAL DIVISION
MARION LABORATORIES, INC.
KANSAS CITY, MISSOURI 64137



This is how an arthritis patient's joints often feel.

You can help these patients feel better with one-a-day FELDENE (piroxicam).
For good reasons:

- it's effective—proven relief of the pain and inflammation of rheumatoid arthritis and osteoarthritis in millions of patients, in 80 countries all around the world.
- it's efficient—once daily, 20-mg dose provides round-the-clock relief, improves compliance and remains effective during long-term therapy, maintaining 24-hour therapeutic blood levels once steady state is reached in 7 to 12 days.
- it's preferred—in an open multi-center study, the antiarthritic preferred by physicians for their patients was FELDENE.[1]

Feldene® *ONE-A-DAY*

(PIROXICAM) 20 mg capsules

Please see a brief summary of FELDENE (piroxicam) prescribing information on the following page.

Feldene®
(PIROXICAM) 20 mg capsules

Rated better by physicians in an open multicenter trial

INVESTIGATORS' COMPARATIVE GLOBAL EVALUATIONS
(Physicians rated Feldene therapy as "better than," "equal to," or "inferior to" previous therapy based on global evaluations of patients' overall response.)



(Adapted from Dessain P. in *Postgrad Med*, April 1982[1])

Investigators' global comparisons of Feldene and previous medications in multicenter open trials by 156 physicians in 749 osteoarthritis patients who had been on previous drug therapy. The above chart includes only those drugs available in the U.S. Average FELDENE dose was 20 mg/day.

REDUCTION IN PAIN AND STIFFNESS
Patients with osteoarthritis evaluated over 6 months on Feldene (mean dose of 20 mg/day) therapy showed dramatic reduction in pain and stiffness.



(Adapted from Dessain P. in *Postgrad Med*, April 1982[1])

Multicenter long-term follow-up of 154 patients who had shown adequate response to piroxicam in short-term trials. 115 patients for whom complete data were available at every assessment visit through 26 weeks.

Reference

1. Dessain P: Efficacy and toleration of piroxicam in general practice: A multicenter study of osteoarthritis. *Postgrad Med* (special report): 76–81, April, 1982.

Brief Summary

FELDENE® (piroxicam) Capsules

CONTRAINDICATIONS: FELDENE (piroxicam) should not be used in patients who have previously exhibited hypersensitivity to it, or in individuals with the syndrome comprised of bronchospasm, nasal polyps and angioedema precipitated by aspirin or other nonsteroidal anti-inflammatory drugs.

WARNINGS: Peptic ulceration, perforation and G.I. bleeding—sometimes severe, and, in some instances fatal—have been reported with patients receiving FELDENE. If FELDENE must be given to patients with a history of upper gastrointestinal tract disease, the patient should be under close supervision (see ADVERSE REACTIONS).

PRECAUTIONS: As with other anti-inflammatory agents, long-term administration to animals results in renal papillary necrosis and related pathology in rats, mice and dogs.

Acute renal failure and hyperkalemia as well as reversible elevations of BUN and serum creatinine have been reported with FELDENE. In addition to reversible changes in renal function, interstitial nephritis, glomerulitis, papillary necrosis and the nephrotic syndrome have been reported with FELDENE.

Although other nonsteroidal anti-inflammatory drugs do not have the same direct effect on platelets that aspirin does, all drugs inhibiting prostaglandin biosynthesis do interfere with platelet function to some degree.

Because of reports of adverse eye findings with nonsteroidal anti-inflammatory agents, it is recommended that patients who develop visual complaints during treatment with FELDENE have ophthalmic evaluation.

As with other nonsteroidal anti-inflammatory drugs, borderline elevations of one or more liver tests may occur in up to 15% of patients. A patient with symptoms and/or signs suggesting liver dysfunction, or in whom abnormal liver tests have occurred, should be evaluated for evidence of the development of more severe hepatic reaction while on therapy with FELDENE.

Severe hepatic reactions, including jaundice and cases of fatal hepatitis have been reported with FELDENE. Although such reactions are rare, if abnormal liver tests persist or worsen, if clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., eosinophilia, rash, etc.), FELDENE should be discontinued. (See also ADVERSE REACTIONS.)

Although at the recommended dose of 20 mg/day of FELDENE increased fecal blood loss due to gastrointestinal irritation did not occur, in about 4% of the patients treated with FELDENE alone or concomitantly with aspirin, reductions in hemoglobin and hematocrit values were observed.

Peripheral edema has been observed in approximately 2% of the patients treated with FELDENE. Therefore, FELDENE should be used with caution in patients with heart failure, hypertension or other conditions predisposing to fluid retention.

A combination of dermatological and/or allergic signs and symptoms suggestive of serum sickness have occasionally occurred in conjunction with the use of FELDENE. These include arthralgias, pruritus, fever, fatigue, and rash including vesiculo bullous reactions and exfoliative dermatitis.

DRUG INTERACTIONS: Interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing. Therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs.

Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels.

Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. It is recommended that plasma lithium levels be monitored when initiating, adjusting and discontinuing FELDENE.

Carcinogenesis, Chronic Animal Toxicity and Impairment of Fertility: Subacute and chronic toxicity studies have been carried out in rats, mice, dogs, and monkeys.

The pathology most often seen was that characteristically associated with the animal toxicology of anti-inflammatory agents: renal papillary necrosis (see PRECAUTIONS) and gastrointestinal lesions.

In classical studies in laboratory animals, piroxicam did not show any teratogenic potential.

Reproductive studies revealed no impairment of fertility in animals.

Pregnancy and Nursing Mothers: Like other drugs which inhibit the synthesis and release of prostaglandins, piroxicam administration continued late into pregnancy increased the incidence of dystocia and delayed parturition in animals. Gastrointestinal tract toxicity was increased in pregnant females in the last trimester of pregnancy compared to non-pregnant females in earlier trimesters of pregnancy.

FELDENE is not recommended for use in nursing mothers or in pregnant women because of the animal findings and since safety for such use has not been established in humans.

Use in Children: Dosage recommendations and indications for use in children have not been established.

ADVERSE REACTIONS: Gastrointestinal symptoms are the most prominent side effects, occurring in approximately 20% of the patients, which in most instances did not interfere with the course of therapy. Of the patients experiencing gastrointestinal side effects, approximately 5% discontinued therapy with an overall incidence of peptic ulceration of about 1%.

Adverse reactions are listed below by body system for all patients in clinical trials with FELDENE at doses of 20 mg/day.

Incidence Greater Than 1%: The following adverse reactions occurred more frequently than 1 in 100.

Gastrointestinal: stomatitis, anorexia, epigastric distress,* nausea,* constipation, abdominal discomfort, flatulence, diarrhea, abdominal pain, indigestion

Hematological: decreases in hemoglobin* and hematocrit* (see PRECAUTIONS), anemia, leucopenia, eosinophilia

Dermatologic: pruritus, rash

Central Nervous System: dizziness, somnolence, vertigo

Urogenital: BUN and creatinine elevations (see PRECAUTIONS)

Body as a Whole: headache, malaise

Special Senses: tinnitus

Cardiovascular/Respiratory: edema (see PRECAUTIONS)

*Reactions occurring in 3% to 9% of patients treated with FELDENE (piroxicam)

Reactions occurring in 1% to 3% of patients are unmarked.

Incidence Less Than 1% (Causal Relationship Probable): The following adverse reactions occurred less frequently than 1 in 100. The probability exists that there is a causal relationship between FELDENE and these reactions.

Gastrointestinal: liver function abnormalities, jaundice, hepatitis (see PRECAUTIONS), vomiting, hematemesis, melena, gastrointestinal bleeding, perforation and ulceration (see WARNINGS), dry mouth

Hematological: thrombocytopenia, petechial rash, ecchymosis, bone marrow depression including aplastic anemia, epistaxis

Dermatologic: sweating, erythema, bruising, desquamation, exfoliative dermatitis, erythema multiforme, toxic epidermal necrolysis, Stevens-Johnson syndrome, vesiculo bullous reactions, photoallergic skin reactions

Central Nervous System: depression, insomnia, nervousness

Urogenital: hematuria, proteinuria, interstitial nephritis, renal failure, hyperkalemia, glomerulitis, papillary necrosis, nephrotic syndrome (see PRECAUTIONS)

Body as a Whole: pain (colic), fever, flu-like syndrome (see PRECAUTIONS)

Special Senses: swollen eyes, blurred vision, eye irritations

Cardiovascular/Respiratory: hypertension, worsening of congestive heart failure (see PRECAUTIONS), exacerbation of angina

Metabolic: hypoglycemia, hyperglycemia, weight increase, weight decrease

Hypersensitivity: anaphylaxis, bronchospasm, urticaria/angioedema, vasculitis, "serum sickness" (see PRECAUTIONS)

Incidence Less Than 1% (Causal Relationship Unknown): Other adverse reactions were reported with a frequency of less than 1 in 100, but a causal relationship between FELDENE and the reaction could not be determined.

Gastrointestinal: pancreatitis

Dermatologic: onycholysis, loss of hair

Central Nervous System: akathisia, hallucinations, mood alterations, dream abnormalities, mental confusion, paresthesias

Urogenital System: dysuria

Body as a Whole: weakness

Cardiovascular/Respiratory: palpitations, dyspnea

OVERDOSAGE: In the event treatment for overdosage is required, the long plasma half-life of piroxicam should be considered. The absence of experience with acute overdosage precludes characterization of sequelae and recommendations of specific antidotal efficacy at this time. It is reasonable to assume that the standard measures of gastric evacuation and general supportive therapy would apply. In addition to supportive measures, the use of activated charcoal may effectively reduce the absorption and reabsorption of piroxicam. Experiments in dogs have demonstrated that the use of multiple-dose treatments with activated charcoal could reduce the half-life of piroxicam elimination from 27 hours (without charcoal) to 11 hours and reduce the systemic bioavailability of piroxicam by as much as 37% when activated charcoal is given as late as 6 hours after administration of piroxicam.

ADMINISTRATION AND DOSAGE: Rheumatoid Arthritis, Osteoarthritis: It is recommended that FELDENE therapy be initiated and maintained at a single daily dose of 20 mg. If desired, the daily dose may be divided.

Dosage recommendations and indications for use in children have not been established.

More detailed professional information available on request.

Pfizer LABORATORIES DIVISION
PFIZER INC.

A Near-Spotless Record.

Other OCs claim it. We show it.[1*]

In clinical trials, Lo/Ovral was practically perfect in holding spotting and breakthrough bleeding to a minimum.[†]

	SPOTTING	BREAKTHROUGH BLEEDING
Cycle 1	10.6%	8.8%
Cycle 3	6.3%	3.3%
Total Cycles[‡]	4.2%	2.9%

Lo/Ovral® offers less breakthrough bleeding and spotting, along with high contraceptive efficacy, at a low dose—just 30 mcg ethinyl estradiol and 0.3 mg norgestrel.

LOW DOSE

LO/OVRAL® 30 mcg

each tablet contains 0.3 mg norgestrel with 0.03 mg ethinyl estradiol, Wyeth.

1. Dickey RP: Managing Contraceptive Pill Patients, 3rd ed., Durant, Oklahoma, Creative Informatics, Inc., 1983.

*Rates are derived from separate studies from different investigators in several population groups and cannot be compared precisely.

†Serious as well as minor adverse reactions have been reported following the use of all oral contraceptives.

‡Data on file for 22,489 total cycles, Wyeth Laboratories. **See important information on following page.**

IN BRIEF:

Indications and Usage—LO/OVRAL® is indicated for the prevention of pregnancy in women who elect to use oral contraceptives (OC's) as a method of contraception.

Contraindications—OC's should not be used in women with any of the following conditions:

1. Thrombophlebitis or thromboembolic disorders.
2. A past history of deep-vein thrombophlebitis or thromboembolic disorders.
3. Cerebral-vascular or coronary-artery disease.
4. Known or suspected carcinoma of the breast.
5. Known or suspected estrogen-dependent neoplasia.
6. Undiagnosed abnormal genital bleeding.
7. Known or suspected pregnancy (see Warning No. 5).
8. Benign or malignant liver tumor which developed during use of OC's or other estrogen-containing products.

Warnings

Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives should be strongly advised not to smoke.

The use of oral contraceptives is associated with increased risk of several serious conditions, including thromboembolism, stroke, myocardial infarction, hepatic adenoma, gallbladder disease, hypertension. Practitioners prescribing oral contraceptives should be familiar with the following information relating to these risks.

1. *Thromboembolic Disorders and Other Vascular Problems*—An increased risk of thromboembolic and thrombotic disease associated with use of OC's is well established. Three principal studies in Great Britain and 3 in the U.S. have demonstrated increased risk of fatal and nonfatal venous thromboembolism and stroke, both hemorrhagic and thrombotic. These studies estimate that users of OC's are 4 to 11 times more likely than nonusers to develop these diseases without evident cause.

CEREBROVASCULAR DISORDERS—In a collaborative American study of cerebrovascular disorders in women with and without predisposing causes, it was estimated that the risk of hemorrhagic stroke was 2.0 times greater in users than nonusers and the risk of thrombotic stroke was 4 to 9.5 times greater in users than in nonusers.

MYOCARDIAL INFARCTION (MI)—An increased risk of MI associated with use of OC's has been reported, confirming a previously suspected association. These studies, conducted in the UK, found, as expected, that the greater the number of underlying risk factors for coronary artery disease (cigarette smoking, hypertension, hypercholesterolemia, obesity, diabetes, history of pre-eclamptic toxemia) the higher the risk of developing MI, regardless of whether the patient was an OC user or not. OC's, however, were found to be a clear additional risk factor. In terms of relative risk, it has been estimated that OC users who do not smoke (smoking is considered a major predisposing condition to MI) are about twice as likely to have a fatal MI as nonusers who do not smoke. OC users who are also smokers have about a 5-fold increased risk of fatal MI compared to users who do not smoke, but about a 10- to 12-fold increased risk compared to nonusers who do not smoke. Furthermore, amount of smoking is also an important factor. In determining importance of these relative risks, however, baseline rates for various age groups must be given serious consideration. Importance of other predisposing conditions mentioned above in determining relative and absolute risks has not as yet been quantified; quite likely the same synergistic action exists, but perhaps to a lesser extent.

RISK OF DOSE—In an analysis of data derived from several national adverse-reaction reporting systems, British investigators concluded that risk of thromboembolism, including coronary thrombosis, is directly related to dose of estrogen in OC's. Preparations containing 100 mcg or more of estrogen were associated with higher risk of thromboembolism than those containing 50-80 mcg. Their analysis did suggest, however, that quantity of estrogen may not be the sole factor involved. This finding has been confirmed in the U.S.

ESTIMATE OF EXCESS MORTALITY FROM CIRCULATORY DISEASES—A large prospective study carried out in the UK estimated the mortality rate per 100,000 women per year from diseases of the circulatory system for users and nonusers of OC's according to age, smoking habits, and duration of use. Overall excess death rate annually from circulatory diseases for OC users was estimated to be 20 per 100,000 (ages 15-34—5/100,000, ages 35-44—33/100,000; ages 45-49—140/100,000), risk being concentrated in older women, in those with long duration of use, and in cigarette smokers. It was not possible, however, to examine interrelationships of age, smoking, and duration of use, nor to compare effects of continuous vs. intermittent use. Although the study showed a 10-fold increase in death due to circulatory diseases in users for 5 or more years, all these deaths occurred in women 35 or older. Until larger numbers of women under 35 with continuous use for 5 or more years are available, it is not possible to assess magnitude of relative risk for this younger group. Available data from a variety of sources have been analyzed to estimate risk of death associated with various methods of contraception. Estimates of risk of death for each method include combined risk of contraceptive method (e.g., thromboembolic and thrombotic disease in the case of OC's) plus risk attributable to pregnancy or abortion in event of method failure. This latter risk varies with effectiveness of method. The study concluded that mortality associated with all methods of birth control is low and below that associated with childbirth, with the exception of OC's in women over 40 who smoke. Lowest mortality is associated with condom or diaphragm backed up by early abortion. Risk of thromboembolic and thrombotic disease associated with OC's increases with age after about 30 and, for MI, is further increased by hypertension, hypercholesterolemia, obesity, diabetes, or history of pre-eclamptic toxemia, and especially cigarette smoking. Physician and patient should be alert to earliest manifestations of thromboembolic and thrombotic disorders (e.g., thrombophlebitis, pulmonary embolism, cerebrovascular insufficiency, coronary occlusion, retinal thrombosis, and mesenteric thrombosis). Should any of these occur or be suspected, the drug should be discontinued immediately. A 4- to 6-fold increased risk of postsurgery thromboembolic complications has been reported in OC users.

If feasible, OC's should be discontinued at least 4 weeks before surgery of a type associated with increased risk of thromboembolism or prolonged immobilization.

PERSISTENCE OF RISK OF VASCULAR DISORDERS—Findings from one study in Britain involving cerebrovascular disease and another in the U.S. concerning MI suggest an increased risk of these conditions in users of OC's persists after discontinuation of the OC's. In the British study, risk of cerebrovascular disease remained elevated in former OC users for at least 6 years after discontinuation. In the U.S. study, increased risk of MI persisted for at least 9 years in women 40 to 49 years old who had used OC's for 5 or more years. Findings in both studies require confirmation since they are inconsistent with other published information.

2. *Ocular Lesions*—There have been reports of neuro-ocular lesions such as optic neuritis or retinal thrombosis associated with use of OC's. Discontinue OC's if there is unexplained, sudden or gradual, partial or complete loss of vision; onset of proptosis or diplopia; papilledema; or retinal-vascular lesions, and institute appropriate diagnostic and therapeutic measures.

3. *Carcinoma*—Long-term continuous administration of either natural or synthetic estrogen in certain animal species increases frequency of carcinoma of the breast, cervix, vagina, and liver. Certain synthetic progestogens, none currently contained in OC's, have been noted to increase incidence of mammary nodules, benign and malignant, in dogs. In humans, 3 case-control studies have reported an increased risk of endometrial carcinoma associated with prolonged use of exogenous estrogen in postmenopausal women. One publication reported on the first 21 cases submitted by physicians to a registry of cases of adenocarcinoma of the endometrium in women under 40 on OC's. Of cases found in women without predisposing risk factors (e.g., irregular bleeding at the time OC's were first given, polycystic ovaries), nearly all occurred in women who had used a sequential OC. These are no longer marketed. No evidence has been reported suggesting increased risk of endometrial cancer in users of conventional combination or progestogen-only OC's. Several studies have found no increase in breast cancer in women taking OC's or estrogens. One study, however, while also noting no overall increased risk of breast cancer in women on OC's, found an excess risk in subgroups of OC users with documented benign breast disease. Reduced occurrence of benign breast tumors in users of OC's has been well documented. In summary, there is at present no confirmed evidence from human studies of increased risk of cancer associated with OC's. Close clinical surveillance of all women on OC's is, nevertheless, essential. In all cases of undiagnosed persistent or recurrent abnormal vaginal bleeding, appropriate diagnostic measures should be taken to rule out malignancy. Women with a strong family history of breast cancer or with breast nodules, fibrocystic disease, or abnormal mammograms should be monitored with particular care if they elect to use OC's.

4. *Hepatic Tumors*—Benign hepatic adenomas have been found to be associated with use of OC's. One study showed that OC's with high hormonal potency were associated with higher risk than lower potency OC's. Although benign, hepatic adenomas may rupture and may cause death through intra-abdominal hemorrhage. This has been reported in short-term as well as long-term users. Two studies relate risk with duration of use of OC's, the risk being much greater after 4 or more years' use. While hepatic adenoma is rare, it should be considered in women presenting abdominal pain and tenderness, abdominal mass or shock. A few cases of hepatocellular carcinoma have been reported in women on OC's. Relationship of these drugs to this type of malignancy is not known.

5. *Use in or Immediately Preceding Pregnancy, Birth Defects in Offspring, and Malignancy in Female Offspring*—Use of female sex hormones—both estrogenic and progestational agents—during early pregnancy may seriously damage the offspring. It has been shown that females exposed in utero to diethylstilbestrol, a nonsteroidal estrogen, have increased risk of developing in later life a form of vaginal or cervical cancer ordinarily extremely rare. This risk has been estimated to be of the order of 1 in 1,000 exposures or less. Although there is no evidence now that OC's further enhance risk of developing this type of malignancy, such patients should be monitored with particular care if they elect to use OC's. Furthermore, 30 to 90% of such exposed women have been found to have epithelial changes of the vagina and cervix. Although these changes are histologically benign, it is not known whether this condition is a precursor of vaginal malignancy. Male children so exposed may develop abnormalities of the urogenital tract. Although similar data are not available with use of other estrogens, it cannot be presumed they would not induce similar changes. An increased risk of congenital anomalies, including heart defects and limb defects, has been reported with use of sex hormones, including OC's, in pregnancy. One case control study estimated a 4.7-fold increase in risk of limb-reduction defects in infants exposed in utero to sex hormones (OC's, hormonal withdrawal tests for pregnancy, or attempted treatment for threatened abortion). Some exposures involved only a few days. Data suggest that risk of limb-reduction defects in exposed fetuses is somewhat less than 1 in 1,000 live births. In the past, female sex hormones have been used during pregnancy in an attempt to treat threatened or habitual abortion. There is considerable evidence that estrogens are ineffective for these indications, and there is no evidence from well-controlled studies that progestogens are effective. There is some evidence that triploidy and possibly other types of polyploidy are increased among abortuses from women who become pregnant soon after ceasing OC's. Embryos with these anomalies are virtually always aborted spontaneously. Whether there is an overall increase in spontaneous abortion of pregnancies conceived soon after stopping OC's is unknown. It is recommended that, for any patient who has missed 2 consecutive periods, pregnancy should be ruled out before continuing OC's. If the patient has not adhered to the prescribed schedule, the possibility of pregnancy should be considered at time of first missed period, and further use of OC's should be withheld until pregnancy has been ruled out. If pregnancy is confirmed, the patient should be apprised of the potential risks to the fetus, and advisability of continuation of the pregnancy should be discussed. It is also recommended that women who discontinue OC's with intent of becoming pregnant use an alternate form of contraception for a period of time before attempting to conceive. Many clinicians recommend 3 months, although no precise information is available on which to base this. The administration of progestogen-estrogen combinations to induce withdrawal bleeding should not be used as a test of pregnancy.

6. *Gallbladder Disease*—Studies report increased risk of surgically confirmed gallbladder disease in users of OC's and estrogens. In one study, increased risk appeared after 2 years' use and doubled after 4 or 5 years' use. In one of the other studies, increased risk was apparent between 6 and 12 months' use.

7. *Carbohydrate and Lipid Metabolic Effects*—Decrease in glucose tolerance has been observed in a significant percentage of patients on OC's. For this reason, prediabetic and diabetic patients should be carefully observed while on OC's. Increase in triglycerides and total phospholipids has been observed in patients on OC's; clinical significance of this finding remains to be defined.

8. *Elevated Blood Pressure*—Increase in blood pressure has been reported in patients on OC's. In some women, hypertension may occur within a few months of beginning OC's. In the 1st year of use, prevalence of women with hypertension is low in users and may be no higher than that of a comparable group of nonusers. Prevalence in users increases, however, with longer exposure, and in the 5th year of use is 2½ to 3 times the reported prevalence in the 1st year. Age is also strongly correlated with development of hypertension in OC users. Women who previously have had hypertension during pregnancy may be more likely to develop elevation of blood pressure on OC's. Hypertension that develops as a result of taking OC's usually returns to normal after discontinuing the drug.

9. *Headache*—Onset or exacerbation of migraine or development of headache of a new pattern which is recurrent, persistent, or severe, requires discontinuation of OC's and evaluation of the cause.

10. *Bleeding Irregularities*—Breakthrough bleeding, spotting, and amenorrhea are frequent reasons for patients discontinuing OC's. In breakthrough bleeding, as in all cases of irregular vaginal bleeding, nonfunctional causes should be borne in mind.

In undiagnosed persistent or recurrent abnormal bleeding from the vagina, adequate diagnostic measures are indicated to rule out pregnancy or malignancy. If pathology has been excluded, time or change to another OC may solve the problem. Changing to an OC with a higher estrogen content, while potentially useful in minimizing menstrual irregularity, should be done only if necessary, since this may increase risk of thromboembolic disease. Women with past history of oligomenorrhea or secondary amenorrhea or young women without regular cycles may have a tendency to remain anovulatory or to become amenorrheic after discontinuing OC's. Women with these pre-existing problems should be advised of this possibility and encouraged to use other methods. Post-use anovulation, possibly prolonged, may also occur in women without previous irregularities.

11. *Ectopic Pregnancy*—Ectopic as well as intrauterine pregnancy may occur in contraceptive failures.

12. *Breast-feeding*—OC's given in the postpartum period may interfere with lactation and decrease quantity and quality of breast milk. Furthermore, a small fraction of the hormones in OC's has been identified in the milk of mothers on OC's; effects, if any, on the breast-fed child have not been determined. If feasible, defer OC's until infant has been weaned.

Precautions GENERAL—1. A complete medical and family history should be taken prior to initiation of OC's. Pretreatment and periodic physical examinations should include special reference to blood pressure; breasts, abdomen and pelvic organs, including Pap smear and relevant laboratory tests.

As a general rule OC's should not be prescribed for longer than 1 year without another physical examination.

2. Under influence of estrogen-progestogen preparations, pre-existing uterine leiomyomata may increase in size.

3. Patients with history of psychic depression should be carefully observed and the drug discontinued if depression recurs to a serious degree. Patients becoming significantly depressed while on OC's should stop OC's and use an alternate method to try to determine whether the symptom is drug related.

4. OC's may cause some degree of fluid retention. They should be prescribed with caution, and only with careful monitoring, in patients with conditions which might be aggravated by fluid retention, such as convulsive disorders, migraine syndrome, asthma, or cardiac or renal insufficiency.

5. Patients with a past history of jaundice during pregnancy have an increased risk of recurrence while on OC's. If jaundice develops, OC's should be discontinued.

6. Steroid hormones may be poorly metabolized in patients with impaired liver function and should be administered with caution.

7. OC users may have disturbances in normal tryptophan metabolism which may result in a relative pyridoxine deficiency. Clinical significance is undetermined.

8. Serum folate levels may be depressed by OC's. Since the pregnant woman is predisposed to development of folate deficiency and incidence of folate deficiency increases with increasing gestation, it is possible that if a woman becomes pregnant shortly after stopping OC's, she may have a greater chance of developing folate deficiency and complications attributed to this deficiency.

9. The pathologist should be advised of OC therapy when relevant specimens are submitted.

10. Certain endocrine- and liver-function tests and blood components may be affected by estrogen-containing OC's: a. Increased sulfobromophthalein retention; b. Increased prothrombin and factors VII, VIII, IX, and X; decreased antithrombin 3; increased norepinephrine-induced platelet aggregability c. Increased thyroid-binding globulin (TBG) leading to increased circulating total thyroid hormone, as measured by protein-bound iodine (PBI), T4 by column, or T4 by radioimmunoassay. Free T3 resin uptake is decreased, reflecting the elevated TBG; free T4 concentration is unaltered. d. Decreased pregnanediol excretion. e. Reduced response to metyrapone test.

Information for the Patient—See Patient Package Labeling.

Drug Interactions Reduced efficacy and increased incidence of breakthrough bleeding have been associated with concomitant use of rifampin. A similar association has been suggested with barbiturates, phenylbutazone, phenytoin sodium, ampicillin and tetracycline.

Carcinogenesis—See Warnings on carcinogenic potential of OC's.

Pregnancy Category X. See Contraindications, Warnings.

Nursing Mothers See Warnings.

Adverse Reactions An increased risk of these serious adverse reactions has been associated with use of OC's (see Warnings): thrombophlebitis, pulmonary embolism, coronary thrombosis, cerebral thrombosis, cerebral hemorrhage, hypertension, gallbladder disease, benign hepatomas, congenital anomalies.

There is evidence of an association between the following conditions and use of OC's although additional confirmatory studies are needed: mesenteric thrombosis, neuro-ocular lesions, e.g., retinal thrombosis and optic neuritis.

The following adverse reactions have been reported in patients on OC's and are believed to be drug-related. Nausea and/or vomiting, usually the most common adverse reactions, occur in approximately 10 percent or less of patients during the first cycle. Other reactions, as a general rule, are seen much less frequently or only occasionally. Gastrointestinal symptoms (such as abdominal cramps and bloating), breakthrough bleeding, spotting, change in menstrual flow, dysmenorrhea, amenorrhea during and after treatment, temporary infertility after discontinuance of treatment, edema, chloasma or melasma which may persist, breast changes: tenderness, enlargement, and secretion; change in weight (increase or decrease); change in cervical erosion and cervical secretion; possible diminution in lactation when given immediately postpartum; cholestatic jaundice; migraine; increase in size of uterine leiomyomata; rash (allergic); mental depression; reduced tolerance to carbohydrates, vaginal candidiasis; change in corneal curvature (steepening), intolerance to contact lenses.

The following adverse reactions have been reported in users of OC's, and the association has been neither confirmed nor refuted: premenstrual-like syndrome, cataracts; changes in libido, chorea; changes in appetite, cystitis-like syndrome, headache, nervousness, dizziness, hirsutism, loss of scalp hair, erythema multiforme, erythema nodosum, hemorrhagic eruption, vaginitis, porphyria.

Acute Overdose Serious ill effects have not been reported following acute ingestion of large doses of OC's by young children. Overdosage may cause nausea, and withdrawal bleeding may occur in females.

LO/OVRAL® each tablet contains 0.3 mg norgestrel with 0.03 mg ethinyl estradiol.

Wyeth Laboratories
Philadelphia, PA 19101

Easy To Take



Keflex®
cephalexin

Additional information available to the profession on request.

DISTA

420113

Dista Products Company
Division of Eli Lilly and Company
Indianapolis, Indiana 46285
Mfd. by Eli Lilly Industries, Inc.
Carolina, Puerto Rico 00630

Put the BALANCE SHEET in your favor with PSC Staff Leasing!



With over 10 YEARS of Staff Leasing* PSC *will put the Balance Sheet in YOUR favor....

Call or Write Today

PSC Practice Service Corporation

Bay Area
115 Sansome St. #812
San Francisco, CA 94104
(415) 433-4210

Los Angeles
16000 Ventura Blvd., #1205
Encino, CA 91436
(213) 872-2508

San Diego
2522 Clairemont Dr., #204
San Diego, CA 92117
(619) 462-9384

Please send information on **PSC** Staff Leasing

NAME: _____

ADDRESS: _____

CITY: _____ STATE: _____ ZIP: _____

TELEPHONE (_____) _____

CONTACT: _____

Benefits diuretics cannot offer . . . Once-daily INDERAL LA (propranolol HCl) provides smooth, 24-hour control of blood pressure plus the cardiovascular benefits of the world's leading beta blocker. And INDERAL LA provides a high degree of patient acceptance—without potassium problems.

Experience no other beta blocker can match . . . Once-daily INDERAL LA delivers the proven performance and safety profile of INDERAL tablets—confirmed by millions of patients during 16 years of clinical use. INDERAL LA should not be used in congestive heart failure, sinus bradycardia, heart block greater than first degree, or bronchial asthma.



Start with 80 mg once daily... Dosage may be increased to 120 mg or 160 mg once daily as needed to achieve additional control. Please see next page for further details and brief summary of prescribing information.

ONCE-DAILY INDERAL® LA

(PROPRANOLOL HCl) LONG ACTING CAPSULES

80 mg 120 mg 160 mg

Just once each day for initial therapy in hypertension.

Ayerst

Just once each day for initial therapy in HYPERTENSION.

ONCE-DAILY

INDERAL® LA

(PROPRANOLOL HCl) LONG ACTING CAPSULES



80 mg 120 mg 160 mg

BRIEF SUMMARY *(FOR FULL PRESCRIBING INFORMATION, SEE PACKAGE CIRCULAR.)*
INDERAL* LA brand of propranolol hydrochloride **(Long Acting Capsules)**
DESCRIPTION. Inderal LA is formulated to provide a sustained release of propranolol hydrochloride. Inderal LA is available as 80 mg, 120 mg, and 160 mg capsules.
CLINICAL PHARMACOLOGY. INDERAL is a nonselective beta-adrenergic receptor blocking agent possessing no other autonomic nervous system activity. It specifically competes with beta-adrenergic receptor stimulating agents for available receptor sites. When access to beta-receptor sites is blocked by INDERAL, the chronotropic, inotropic, and vasodilator responses to beta-adrenergic stimulation are decreased proportionately.

INDERAL LA Capsules (80, 120, and 160 mg) release propranolol HCl at a controlled and predictable rate. Peak blood levels following dosing with INDERAL LA occur at about 6 hours and the apparent plasma half-life is about 10 hours. When measured at steady state over a 24-hour period the areas under the propranolol plasma concentration-time curve (AUCs) for the capsules are approximately 60% to 65% of the AUCs for a comparable divided daily dose of INDERAL tablets. The lower AUCs for the capsules are due to greater hepatic metabolism of propranolol, resulting from the slower rate of absorption of propranolol. Over a twenty-four (24) hour period, blood levels are fairly constant for about twelve (12) hours then decline exponentially.

INDERAL LA should not be considered a simple mg for mg substitute for conventional propranolol and the blood levels achieved do not match (are lower than) those of two to four times daily dosing with the same dose. When changing to INDERAL LA from conventional propranolol, a possible need for retitration upwards should be considered especially to maintain effectiveness at the end of the dosing interval. In most clinical settings, however, such as hypertension or angina where there is little correlation between plasma levels and clinical effect, INDERAL LA has been therapeutically equivalent to the same mg dose of conventional INDERAL as assessed by 24-hour effects on blood pressure and on 24-hour exercise responses of heart rate, systolic pressure and rate pressure product. INDERAL LA can provide effective beta blockade for a 24-hour period.

The mechanism of the antihypertensive effect of INDERAL has not been established. Among the factors that may be involved in contributing to the antihypertensive action are (1) decreased cardiac output, (2) inhibition of renin release by the kidneys, and (3) diminution of tonic sympathetic nerve outflow from vasomotor centers in the brain. Although total peripheral resistance may increase initially, it readjusts to or below the pretreatment level with chronic use. Effects on plasma volume appear to be minor and somewhat variable. INDERAL has been shown to cause a small increase in serum potassium concentration when used in the treatment of hypertensive patients.

In angina pectoris, propranolol generally reduces the oxygen requirements at any given level of effort by blocking the catecholamine-induced increases in the heart rate, systolic blood pressure, and the velocity and extent of myocardial contraction. Propranolol may increase oxygen requirements by increasing left ventricular fiber length, end-systolic pressure and systolic ejection period. The net physiologic effect of beta-adrenergic blockade is usually advantageous and is manifested during exercise by delayed onset of pain and increased work capacity.

In dosages greater than required for beta blockade, INDERAL also exerts a quinidine-like or anesthetic-like membrane action which affects the cardiac action potential. The significance of the membrane action in the treatment of arrhythmias is uncertain.

The mechanism of the antimigraine effect of propranolol is not established. Beta-adrenergic receptors have been demonstrated in cranial blood vessels.

Beta receptor blockade can be useful in conditions in which there is pathologic but functional changes, sympathetic activity is detrimental. But it is also in situations in which sympathetic stimulation is vital. For example, in patients with severely damaged hearts, adequate ventricular function is maintained by virtue of sympathetic drive which should be preserved. In the presence of AV block, greater than first degree, beta blockade may prevent the necessary facilitating effect of sympathetic activity on conduction. Beta blockade results in bronchial constriction by interfering with adrenergic bronchodilator activity which should be preserved in patients subject to bronchospasm.

Propranolol is not significantly dialyzable.
INDICATIONS AND USAGE. Hypertension: INDERAL LA is indicated in the management of hypertension; it may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic. INDERAL LA is not indicated in the management of hypertensive emergencies.

Angina Pectoris Due to Coronary Atherosclerosis: INDERAL LA is indicated for the long-term management of patients with angina pectoris.

Migraine: INDERAL LA is indicated for the prophylaxis of common migraine headache. The efficacy of propranolol in the treatment of a migraine attack that has started has not been established and propranolol is not indicated for such use.

Hypertrophic Subaortic Stenosis: INDERAL LA is useful in the management of hypertrophic subaortic stenosis, especially for treatment of exertional or other stress-induced angina, palpitations, and syncope. INDERAL LA also improves exercise performance. The effectiveness of propranolol hydrochloride in this disease appears to be due to a reduction of the elevated outflow pressure gradient which is exacerbated by beta-receptor stimulation. Clinical improvement may be temporary.
CONTRAINDICATIONS. INDERAL is contraindicated in 1) cardiogenic shock; 2) sinus bradycardia and greater than first degree block; 3) bronchial asthma; 4) congestive heart failure (see WARNINGS) unless the failure is secondary to a tachyarrhythmia treatable with INDERAL.
WARNINGS. CARDIAC FAILURE: Sympathetic stimulation may be a vital component supporting circulatory function in patients with congestive heart failure, and its inhibition by beta blockade may precipitate more severe failure. Although beta blockers should be avoided in overt congestive heart failure, if necessary, they can be used with close follow-up in patients with a history of failure who are well compensated and are receiving digitalis and diuretics. Beta-adrenergic blocking agents do not abolish the inotropic action of digitalis on heart muscle.

IN PATIENTS WITHOUT A HISTORY OF HEART FAILURE, continued use of beta blockers can, in some cases, lead to cardiac failure. Therefore, at the first sign or symptom of heart failure, the patient should be digitalized and/or treated with diuretics, and the response observed closely, or INDERAL should be discontinued (gradually, if possible).

IN PATIENTS WITH ANGINA PECTORIS, there have been reports of exacerbation of angina and, in some cases, myocardial infarction, following abrupt discontinuance of INDERAL therapy. Therefore, when discontinuance of INDERAL is planned the dosage should be gradually reduced over at least a few weeks, and the patient should be cautioned against interruption or cessation of therapy without the physician's advice. If INDERAL therapy is interrupted and exacerbation of angina occurs, it usually is advisable to reinstitute INDERAL therapy and take other measures appropriate for the management of unstable angina pectoris. Since coronary artery disease may be unrecognized, it may be prudent to follow the above advice in patients considered at risk of having occult atherosclerotic heart disease who are given propranolol for other indications.

Nonallergic Bronchospasm (e.g., chronic bronchitis, emphysema)—PATIENTS WITH BRONCHOSPASTIC DISEASES SHOULD IN GENERAL NOT RECEIVE BETA BLOCKERS. INDERAL should be administered with caution since it may block bronchodilation produced by endogenous and exogenous catecholamine stimulation of beta receptors.

MAJOR SURGERY: The necessity or desirability of withdrawal of beta-blocking therapy prior to major surgery is controversial. It should be noted, however, that the impaired ability of the heart to respond to reflex adrenergic stimuli may augment the risks of general anesthesia and surgical procedures.

INDERAL (propranolol HCl), like other beta blockers, is a competitive inhibitor of beta-receptor agonists and its effects can be reversed by administration of such agents, e.g., dobutamine or isoproterenol. However, such patients may be subject to protracted severe hypotension. Difficulty in starting and maintaining the heartbeat has also been reported with beta blockers.

DIABETES AND HYPOGLYCEMIA: Beta-adrenergic blockade may prevent the appearance of certain premonitory signs and symptoms (pulse rate and pressure changes) of acute hypoglycemia in labile insulin-dependent diabetes. In these patients, it may be more difficult to adjust the dosage of insulin.

THYROTOXICOSIS: Beta blockade may mask certain clinical signs of hyperthyroidism. Therefore, abrupt withdrawal of propranolol may be followed by an exacerbation of symptoms of hyperthyroidism, including thyroid storm. Propranolol does not distort thyroid function tests.

IN PATIENTS WITH WOLFF-PARKINSON-WHITE SYNDROME, several cases have been reported in which, after propranolol, the tachycardia was replaced by a severe bradycardia requiring a demand pacemaker. In one case this resulted after an initial dose of 5 mg propranolol.
PRECAUTIONS. *General:* Propranolol should be used with caution in patients with impaired hepatic or renal function. INDERAL is not indicated for the treatment of hypertensive emergencies.

Beta adrenoreceptor blockade can cause reduction of intraocular pressure. Patients should be told that INDERAL may interfere with the glaucoma screening test. Withdrawal may lead to a return of increased intraocular pressure.

Clinical Laboratory Tests: Elevated blood urea levels in patients with severe heart disease, elevated serum transaminase, alkaline phosphatase, lactate dehydrogenase.

DRUG INTERACTIONS: Patients receiving catecholamine-depleting drugs such as reserpine should be closely observed if INDERAL is administered. The added catecholamine-blocking action may produce an excessive reduction of resting sympathetic nervous activity which may result in hypotension, marked bradycardia, vertigo, syncopal attacks, or orthostatic hypotension.

Carcinogenesis, Mutagenesis, Impairment of Fertility: Long-term studies in animals have been conducted to evaluate toxic effects and carcinogenic potential. In 18-month studies in both rats and mice, employing doses up to 150 mg/kg/day, there was no evidence of significant drug-related tumorigenic effects at any of the dosage levels. Reproduction studies in animals did not show any impairment of fertility that was attributable to the drug.

Pregnancy: Pregnancy Category C. INDERAL has been shown to be embryotoxic in animal studies at doses 0 times or greater than the maximum recommended human dose. There are no adequate and well-controlled studies in pregnant women. INDERAL should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers: INDERAL is excreted in human milk. Caution should be exercised when INDERAL is administered to a nursing woman.

Pediatric Use: Safety and effectiveness in children have not been established.
ADVERSE REACTIONS: Adverse effects have been mild and transient and have rarely required withdrawal of therapy.

Cardiovascular: bradycardia; congestive heart failure; intensification of AV block; hypotension; thrombocytopenic purpura; arterial insufficiency, usually of the Raynaud type.

Central Nervous System: lightheadedness; mental depression manifested by insomnia, lassitude, weakness, fatigue; reversible mental depression progressing to catatonia; visual disturbances; hallucinations; an acute reversible syndrome characterized by disorientation for time and place, short-term memory loss, emotional lability, slightly clouded sensorium, and decreased performance on neuropsychometrics.

Gastrointestinal: nausea, vomiting, epigastric distress, abdominal cramping, diarrhea, constipation, mesenteric arterial thrombosis, ischemic colitis.

Allergic: pharyngitis and agranulocytosis, erythematous rash, fever combined with aching and sore throat, laryngospasm and respiratory distress.

Respiratory: bronchospasm.

Hematologic: agranulocytosis, nonthrombocytopenic purpura, thrombocytopenic purpura.

Auto-Immune: In extremely rare instances, systemic lupus erythematosus has been reported.

Miscellaneous: alopecia, LE-like reactions, psoriasiform rashes, dry eyes, male impotence, and Peyronie's disease have been reported rarely. Oculomucocutaneous reactions involving the skin, serous membranes and conjunctivae reported for a beta blocker (practolol) have not been associated with propranolol.
DOSAGE AND ADMINISTRATION. INDERAL LA provides propranolol hydrochloride in a sustained-release capsule for administration once daily. If patients are switched from INDERAL tablets to INDERAL LA capsules, care should be taken to assure that the desired therapeutic effect is maintained. INDERAL LA should not be considered a simple mg for mg substitute for INDERAL. INDERAL LA has different kinetics and produces lower blood levels. Retitration may be necessary especially to maintain effectiveness at the end of the 24-hour dosing interval.

HYPERTENSION—*Dosage must be individualized.* The usual initial dosage is 80 mg INDERAL LA once daily, whether used alone or added to a diuretic. The dosage may be increased to 120 mg once daily or higher until adequate blood-pressure control is achieved. The usual maintenance dosage is 120 to 160 mg once daily. In some instances a dosage of 640 mg may be required. The time needed for full hypertensive response to a given dosage is variable and may range from a few days to several weeks.

ANGINA PECTORIS—*Dosage must be individualized.* Starting with 80 mg INDERAL LA once daily, dosage should be gradually increased at three to seven day intervals until optimum response is obtained. Although individual patients may respond at any dosage level, the average optimum dosage appears to be 160 mg once daily. In angina pectoris, the value and safety of dosage exceeding 320 mg per day have not been established.

If treatment is to be discontinued, reduce dosage gradually over a period of a few weeks (see WARNINGS).

MIGRAINE—*Dosage must be individualized.* The initial oral dose is 80 mg INDERAL LA once daily. The usual effective dose range is 160-240 mg once daily. The dosage may be increased gradually to achieve optimum migraine prophylaxis. If a satisfactory response is not obtained within four to six weeks after reaching the maximum dose, INDERAL LA therapy should be discontinued. It may be advisable to withdraw the drug gradually over a period of several weeks.

HYPERTROPHIC SUBAORTIC STENOSIS—80-160 mg INDERAL LA once daily.

PEDIATRIC DOSAGE—At this time the data on the use of the drug in this age group are too limited to permit adequate directions for use.

*The appearance of INDERAL LA capsules is a registered trademark of Ayerst Laboratories.

8950/284

Ayerst. AYERST LABORATORIES
New York, N.Y. 10017

0.9 MG TABLET
ADDED DOSAGE
PRECISION

THE DISRUPTIVE PATTERN OF VASOMOTOR SYMPTOMS



The sleepgram demonstrates the correlation between hot flushes and waking episodes that can disrupt the menopausal woman's sleep night after night. —adapted from Erlik et al, p 1742.[1]

■ = objectively measured hot flush
o = arousal of patient by investigator at end of the study
W = Waking
R = Rapid Eye Movement (REM)

EFFECTIVE TREATMENT

Hot flushes, with associated immediate-waking episodes, can occur several times a night—severely disrupting the menopausal patient's sleep.[2] The symptoms may also appear during the day and seriously disrupt the patient's life.

Scientific evidence has shown that the symptoms are not purely subjective.[2] In one study, nearly all objectively recorded hot flushes during sleep were associated with immediate waking episodes.[1] They're the most common cause for which menopausal patients seek medical attention.[2] At least 75% of menopausal women experience the symptoms, which persist for over one year in 80% of those afflicted. But 25% to 50% of the women suffer longer than five years.[3]

PREMARIN® (Conjugated Estrogens Tablets, U.S.P.) therapy is effective in reducing the severity and frequency of symptomatic attacks and eliminating them altogether. When moderate to severe vasomotor symptoms are chronically disruptive, provide relief with PREMARIN.

FOR MODERATE TO SEVERE VASOMOTOR SYMPTOMS

PREMARIN®
(CONJUGATED ESTROGENS TABLETS, U.S.P.)

0.3 mg 0.625 mg 0.9 mg 1.25 mg 2.5 mg

The appearance of these tablets is a trademark of Ayerst Laboratories

THE DISTRESSING CONSEQUENCES OF ATROPHIC VAGINITIS



Estrogen levels—to diagnose estrogen deficiency or monitor replacement therapy—are revealed by cytologic examination of vaginal smears. Since estrogen is essential for their maturation, the predominance of superficial cells is an indicator of high estrogen levels—characteristic of the younger woman. Postmenopausal estrogen depletion is characterized by a corresponding decline in superficial cells and a significant rise in parabasal cells.

THERAPY AS SPECIFIC AS THE PROBLEM

Cytologic examination of vaginal smears can be used as part of the diagnosis of estrogen deficiency.[4] Topical application of PREMARIN® (Conjugated Estrogens, U.S.P.) Vaginal Cream may be appropriate.[2] Therapy is concentrated just where it is needed—in the vaginal environment.

PREMARIN Vaginal Cream has been shown to significantly increase the number of superficial cells in menopausal women within one month.[5] It stimulates epithelial proliferation of the vulva and vagina—returning them to a healthier state in one or two weeks. Symptoms such as dryness, burning, and itching are relieved.[2] Vaginal pH reverts to normal acidity. Normal flora are reestablished, reducing the possibility of local or general infection. Dyspareunia, associated with atrophic vaginitis, is also alleviated.

When vaginal atrophy is the only consequence of estrogen deficiency, PREMARIN Vaginal Cream helps return the vaginal environment to its premenopausal state.

Please see last page for brief summary of prescribing information.

FOR ATROPHIC VAGINITIS

PREMARIN®
(CONJUGATED ESTROGENS, U.S.P.) VAGINAL CREAM



0.9 MG TABLET
ADDED DOSAGE
PRECISION

THE DISABLING COURSE OF OSTEOPOROSIS



The graph demonstrates the decrease in cortical thickness that commences just prior to 50 years—the mean menopausal age in women—and accelerates precipitously thereafter. —adapted from Worley, p 204.[6]

THE SOONER TREATMENT BEGINS, THE BETTER

Once osteoporosis is diagnosed, PREMARIN® (Conjugated Estrogens Tablets, U.S.P.) may prove highly beneficial in retarding further bone loss.* PREMARIN treatment should be initiated promptly after osteoporosis is detected to help arrest bone resorption throughout the skeleton, including long bones, pelvic bones, and vertebrae—which are particularly susceptible to trauma. Along with PREMARIN, evaluation of diet, calcium intake, and physical exercise is recommended.

Watching for early warning signals of osteoporosis in high-risk patients is vital. These individuals can be identified by a composite of certain characteristics: white race, slender, slight build, premature or surgical menopause, sedentary life-style, family history of the disease, as well as high caffeine intake, cigarette smoking, and alcoholism.

Osteoporosis affects one of four postmenopausal women.[7] Based on 1980 census data which reports that 23.3 million women were in the 45–64 year age group, over 5 million women may suffer from this condition.[8] Once the damage is done, it is too late to restore bone that has been lost. That's why scientific literature stresses the need for early detection.[9] After osteoporosis is confirmed, early intervention with PREMARIN may be the best course to take.

FOR POSTMENOPAUSAL OSTEOPOROSIS*

PREMARIN®
(CONJUGATED ESTROGENS TABLETS, U.S.P.)

0.3 mg 0.625 mg 0.9 mg 1.25 mg 2.5 mg

The appearance of these tablets is a trademark of Ayerst Laboratories.

*Conjugated Estrogens Tablets have been evaluated as probably effective for treating postmenopausal osteoporosis.

Please see last page for brief summary of prescribing information.

BRIEF SUMMARY *(FOR FULL PRESCRIBING INFORMATION AND PATIENT INFORMATION, SEE PACKAGE CIRCULAR)*

PREMARIN® Brand of Conjugated Estrogens Tablets, U.S.P.
PREMARIN® Brand of Conjugated Estrogens, U.S.P. Vaginal Cream in a nonliquefying base

1. ESTROGENS HAVE BEEN REPORTED TO INCREASE THE RISK OF ENDOMETRIAL CARCINOMA.

Three independent case control studies have reported an increased risk of endometrial cancer in postmenopausal women exposed to exogenous estrogens for more than one year. This risk was independent of the other known risk factors for endometrial cancer. These studies are further supported by the finding that incidence rates of endometrial cancer have increased sharply since 1969 in eight different areas of the United States with population-based cancer reporting systems, an increase which may be related to the rapidly expanding use of estrogens during the last decade. The three case control studies reported that the risk of endometrial cancer in estrogen users was about 4.5 to 13.9 times greater than in nonusers. The risk appears to depend on both duration of treatment and on estrogen dose. In view of these findings, when estrogens are used for the treatment of menopausal symptoms, the lowest dose that will control symptoms should be utilized and medication should be discontinued as soon as possible. When prolonged treatment is medically indicated, the patient should be reassessed on at least a semiannual basis to determine the need for continued therapy. Although the evidence must be considered preliminary, one study suggests that cyclic administration of low doses of estrogen may carry less risk than continuous administration; it therefore appears prudent to utilize such a regimen. Close clinical surveillance of all women taking estrogens is important. In all cases of undiagnosed persistent or recurring abnormal vaginal bleeding, adequate diagnostic measures should be undertaken to rule out malignancy. There is no evidence at present that "natural" estrogens are more or less hazardous than "synthetic" estrogens at equiestrogenic doses.

2. ESTROGENS SHOULD NOT BE USED DURING PREGNANCY.

The use of female sex hormones, both estrogens and progestogens, during early pregnancy may seriously damage the offspring. It has been shown that females exposed in utero to diethylstilbestrol, a non-steroidal estrogen, have an increased risk of developing in later life a form of vaginal or cervical cancer that is ordinarily extremely rare. This risk has been estimated as not greater than 4 per 1000 exposures. Furthermore, a high percentage of such exposed women (from 30 to 90 percent) have been found to have vaginal adenosis, epithelial changes of the vagina and cervix. Although these changes are histologically benign, it is not known whether they are precursors of malignancy. Although similar data are not available with the use of other estrogens, it cannot be presumed they would not induce similar changes. Several reports suggest an association between intrauterine exposure to female sex hormones and congenital anomalies, including congenital heart defects and limb reduction defects. One case control study estimated a 4.7-fold increased risk of limb reduction defects in infants exposed in utero to sex hormones (oral contraceptives, hormone withdrawal tests for pregnancy, or attempted treatment for threatened abortion). Some of these exposures were very short and involved only a few days of treatment. The data suggest that the risk of limb reduction defects in exposed fetuses is somewhat less than 1 per 1000. In the past, female sex hormones have been used during pregnancy in an attempt to treat threatened or habitual abortion. There is considerable evidence that estrogens are ineffective for these indications, and there is no evidence from well controlled studies that progestogens are effective for these uses. If PREMARIN is used during pregnancy, or if the patient becomes pregnant while taking this drug, she should be apprised of the potential risks to the fetus, and the advisability of pregnancy continuation.

DESCRIPTION: PREMARIN (Conjugated Estrogens, U.S.P.) contains a mixture of estrogens, obtained exclusively from natural sources, blended to represent the average composition of material derived from pregnant mares' urine. It contains estrone, equilin, and 17α-dihydroequilin, together with smaller amounts of 17α-estradiol, equilenin, and 17α-dihydroequilenin as salts of their sulfate esters.

INDICATIONS: Based on a review of PREMARIN Tablets by the National Academy of Sciences - National Research Council and/or other information, FDA has classified the indications for use as follows:

Effective: 1. Moderate to severe vasomotor symptoms associated with the menopause. (There is no evidence that estrogens are effective for nervous symptoms or depression without associated vasomotor symptoms, and they should not be used to treat such conditions.)
2. Atrophic vaginitis
3. Kraurosis vulvae
4. Female hypogonadism
5. Female castration
6. Primary ovarian failure
7. Breast cancer (for palliation only) in appropriately selected women and men with metastatic disease.
8. Prostatic carcinoma - palliative therapy of advanced disease.
9. Postpartum breast engorgement – Although estrogens have been widely used for the prevention of postpartum breast engorgement, controlled studies have demonstrated that the incidence of significant painful engorgement in patients not receiving such hormonal therapy is low and usually responsive to appropriate analgesic or other supportive therapy. Consequently, the benefit to be derived from estrogen therapy for this indication must be carefully weighed against the potential increased risk of puerperal thromboembolism associated with the use of large doses of estrogens.

PREMARIN HAS NOT BEEN SHOWN TO BE EFFECTIVE FOR ANY PURPOSE DURING PREGNANCY AND ITS USE MAY CAUSE SEVERE HARM TO THE FETUS (SEE BOXED WARNING).

"Probably" effective: For estrogen deficiency-induced osteoporosis, and only when used in conjunction with other important therapeutic measures such as diet, calcium, physiotherapy, and good general health-promoting measures. Final classification of this indication requires further investigation.

INDICATIONS: PREMARIN (Conjugated Estrogens, U.S.P.) Vaginal Cream is indicated in the treatment of atrophic vaginitis and kraurosis vulvae. PREMARIN Vaginal Cream HAS NOT BEEN SHOWN TO BE EFFECTIVE FOR ANY PURPOSE DURING PREGNANCY AND ITS USE MAY CAUSE SEVERE HARM TO THE FETUS (SEE BOXED WARNING).

CONTRAINDICATIONS: Estrogens should not be used in women (or men) with any of the following conditions: 1. Known or suspected cancer of the breast except in appropriately selected patients being treated for metastatic disease. 2. Known or suspected estrogen-dependent neoplasia. 3. Known or suspected pregnancy (See Boxed Warning). 4. Undiagnosed abnormal genital bleeding. 5. Active thrombophlebitis or thromboembolic disorders. 6. A past history of thrombophlebitis, thrombosis, or thromboembolic disorders associated with previous estrogen use (except when used in treatment of breast or prostatic malignancy).

WARNINGS: Long term continuous administration of natural and synthetic estrogens in certain animal species increases the frequency of carcinomas of the breast, cervix, vagina, and liver. There are now reports that estrogens increase the risk of carcinoma of the endometrium in humans. (See Boxed Warning.) At the present time there is no satisfactory evidence that estrogens given to postmenopausal women increase the risk of cancer of the breast, although a recent study has raised this possibility. There is a need for caution in prescribing estrogens for women with a strong family history of breast cancer or who have breast nodules, fibrocystic disease, or abnormal mammograms. A recent study has reported a 2- to 3-fold increase in the risk of surgically confirmed gallbladder disease in women receiving postmenopausal estrogens.

Adverse effects of oral contraceptives may be expected at the larger doses of estrogen used to treat prostatic or breast cancer or postpartum breast engorgement; it has been shown that there is an increased risk of thrombosis in men receiving estrogens for prostatic cancer and women for postpartum breast engorgement. Users of oral contraceptives have an increased risk of diseases, such as thrombophlebitis, pulmonary embolism, stroke, and myocardial infarction. Cases of retinal thrombosis, mesenteric thrombosis, and optic neuritis have been reported in oral contraceptive users. An increased risk of postsurgery thromboembolic complications has also been reported in users of oral contraceptives. If feasible, estrogen should be discontinued at least 4 weeks before surgery of the type associated with an increased risk of thromboembolism, or during periods of prolonged immobilization. Estrogens should not be used in persons with active thrombophlebitis, thromboembolic disorders, or in persons with a history of such disorders in association with estrogen use. They should be used with caution in patients with cerebral vascular or coronary artery disease. Large doses (5 mg conjugated estrogens per day), comparable to those used to treat cancer of the prostate and breast have been shown to increase the risk of nonfatal myocardial infarction, pulmonary embolism and thrombophlebitis. When doses of this size are used, any of the thromboembolic and thrombotic adverse effects should be considered a clear risk.

Benign hepatic adenomas should be considered in estrogen users having abdominal pain and tenderness, abdominal mass, or hypovolemic shock. Hepatocellular carcinoma has been reported in women taking estrogen-containing oral contraceptives. Increased blood pressure may occur with use of estrogens in the menopause and blood pressure should be monitored with estrogen use. A worsening of glucose tolerance has been observed in patients on estrogen-containing oral contraceptives. For this reason, diabetic patients should be carefully observed. Estrogens may lead to severe hypercalcemia in patients with breast cancer and bone metastases.

PRECAUTIONS: Physical examination and a complete medical and family history should be taken prior to the initiation of any estrogen therapy with special reference to blood pressure, breasts, abdomen, and pelvic organs, and should include a Papanicolaou smear. As a general rule, estrogen should not be prescribed for longer than one year without another physical examination being performed. Conditions influenced by fluid retention, such as asthma, epilepsy, migraine, and cardiac or renal dysfunction, require careful observation. Certain patients may develop manifestations of excessive estrogenic stimulation, such as abnormal or excessive uterine bleeding, mastodynia, etc. Prolonged administration of unopposed estrogen therapy has been reported to increase the risk of endometrial hyperplasia in some patients. Oral contraceptives appear to be associated with an increased incidence of mental depression. Patients with a history of depression should be carefully observed. Preexisting uterine leiomyomata may increase in size during estrogen use. The pathologist should be advised of estrogen therapy when relevant specimens are submitted. If jaundice develops in any patient receiving estrogen, the medication should be discontinued while the cause is investigated. Estrogens should be used with care in patients with impaired liver function, renal insufficiency, metabolic bone diseases associated with hypercalcemia, or in young patients in whom bone growth is not complete.

The following changes may be expected with larger doses of estrogen:

a. Increased sulfobromophthalein retention.

b. Increased prothrombin and factors VII, VIII, IX, and X; decreased antithrombin 3; increased norepinephrine-induced platelet aggregability.

c. Increased thyroid binding globulin (TBG) leading to increased circulating total thyroid hormone, as measured by PBI, T4 by column, or T4 by radioimmunoassay. Free T3 resin uptake is decreased, reflecting the elevated TBG; free T4 concentration is unaltered.

d. Impaired glucose tolerance.

e. Decreased pregnanediol excretion.

f. Reduced response to metyrapone test.

g. Reduced serum folate concentration.

h. Increased serum triglyceride and phospholipid concentration.

As a general principle, the administration of any drug to nursing mothers should be done only when clearly necessary since many drugs are excreted in human milk.

ADVERSE REACTIONS: The following have been reported with estrogenic therapy, including oral contraceptives: breakthrough bleeding; spotting; change in menstrual flow; dysmenorrhea; premenstrual-like syndrome; amenorrhea during and after treatment; increase in size of uterine fibromyomata; vaginal candidiasis; change in cervical erosion and in degree of cervical secretion; cystitis-like syndrome; tenderness, enlargement, secretion (of breasts); nausea, vomiting, abdominal cramps, bloating; cholestatic jaundice; chloasma or melasma which may persist when drug is discontinued; erythema multiforme; erythema nodosum; hemorrhagic eruption; loss of scalp hair; hirsutism; steepening of corneal curvature; intolerance to contact lenses; headache, migraine, dizziness, mental depression, chorea; increase or decrease in weight; reduced carbohydrate tolerance; aggravation of porphyria; edema; changes in libido.

ACUTE OVERDOSAGE: May cause nausea, and withdrawal bleeding may occur in females.

DOSAGE AND ADMINISTRATION:

PREMARIN® Brand of Conjugated Estrogens Tablets, U.S.P.

1. *Given cyclically for short-term use only.* For treatment of moderate to severe *vasomotor* symptoms, atrophic vaginitis, or kraurosis vulvae associated with the menopause (0.3 to 1.25 mg or more daily).

The lowest dose that will control symptoms should be chosen and medication should be discontinued as promptly as possible.

Administration should be cyclic (*e.g.*, three weeks on and one week off).

Attempts to discontinue or taper medication should be made at three to six month intervals.

2. *Given cyclically:* Female hypogonadism. Female castration. Primary ovarian failure. Osteoporosis.

Female hypogonadism – 2.5 to 7.5 mg daily, in divided doses for 20 days, followed by a rest period of 10 days' duration. If bleeding does not occur by the end of this period, the same dosage schedule is repeated. The number of courses of estrogen therapy necessary to produce bleeding may vary depending on the responsiveness of the endometrium.

If bleeding occurs before the end of the 10 day period, begin a 20 day estrogen-progestin cyclic regimen with PREMARIN (Conjugated Estrogens Tablets, U.S.P.), 2.5 to 7.5 mg daily in divided doses, for 20 days. During the last five days of estrogen therapy, give an oral progestin. If bleeding occurs before this regimen is concluded, therapy is discontinued and may be resumed on the fifth day of bleeding.

Female castration and primary ovarian failure – 1.25 mg daily, cyclically. Adjust upward or downward according to response of the patient. For maintenance, adjust dosage to lowest level that will provide effective control.

Osteoporosis (to retard progression) – 1.25 mg daily, cyclically.

3. *Given for a few days:* Prevention of postpartum breast engorgement – 3.75 mg every four hours for five doses, or 1.25 mg every four hours for five days.

4. *Given chronically:* Inoperable progressing prostatic cancer – 1.25 to 2.5 mg three times daily.

Inoperable progressing breast cancer in appropriately selected men and postmenopausal women – 10 mg three times daily for a period of at least three months.

Patients with an intact uterus should be monitored for signs of endometrial cancer and appropriate measures taken to rule out malignancy in the event of persistent or recurring abnormal vaginal bleeding.

PREMARIN® Brand of Conjugated Estrogens, U.S.P. Vaginal Cream

Given cyclically for short-term use only. For treatment of atrophic vaginitis or kraurosis vulvae.

The lowest dose that will control symptoms should be chosen and medication should be discontinued as promptly as possible.

Administration should be cyclic (*e.g.*, three weeks on and one week off).

Attempts to discontinue or taper medication should be made at three to six month intervals.

Usual dosage range: 2 to 4 g daily, intravaginally or topically, depending on the severity of the condition.

Treated patients with an intact uterus should be monitored closely for signs of endometrial cancer and appropriate diagnostic measures should be taken to rule out malignancy in the event of persistent or recurring abnormal vaginal bleeding.

HOW SUPPLIED: PREMARIN (Conjugated Estrogens Tablets, U.S.P.) No. 865 – Each *purple* tablet contains 2.5 mg in bottles of 100 and 1,000. No. 866 – Each *yellow* tablet contains 1.25 mg in bottles of 100 and 1,000. Also in Cycle Pack of 21 and in unit dose package of 100. No. 864 – Each *white* tablet contains 0.9 mg in bottles of 100. Also in Cycle Pack of 21. No. 867 – Each *maroon* tablet contains 0.625 mg in bottles of 100 and 1,000. Also in Cycle Pack of 21 and unit dose package of 100. No. 868 – Each *green* tablet contains 0.3 mg in bottles of 100 and 1,000.

PREMARIN (Conjugated Estrogens, U.S.P.) Vaginal Cream – No. 872 – Each gram contains 0.625 mg Conjugated Estrogens, U.S.P. (Also contains cetyl esters wax, cetyl alcohol, white wax, glyceryl monostearate, propylene glycol monostearate, methyl stearate, phenylethyl alcohol, sodium lauryl sulfate, glycerin, and mineral oil.)

Combination package: Each contains Net Wt. 1½ oz. (42.5 g) tube with one calibrated plastic applicator.

Also Available – Refill package: Each contains Net Wt. 1½ oz. (42.5 g) tube. **8934/584**

Ayerst® AYERST LABORATORIES
New York, N.Y. 10017

PHYSICIANS

We are announcing opportunities for you to serve your country as an Air Force Reserve physician/officer. You can make new professional associations, obtain CME credit and help support the Air Force mission. For those who qualify, retirement credit can be obtained as well as low cost life insurance. One weekend a month plus two weeks a year or less can bring you pride and satisfaction in serving your country.

Call:
(912) 926-5769 Collect

Or Fill Out Coupon and Mail Today!
To: Health Professions Recruiting
4 AF/RSH, McClellan AFB, CA 95652

Name _____

Address _____

City _____ State _____ Zip _____

Phone _____ Prior Service? Yes ___ No ___

Medical Specialty _____ Date of Birth _____

AIR FORCE RESERVE 04-403-1057

A GREAT WAY TO SERVE

1058

When seasonal allergy strikes

Arthritis pain after 50

Age is no barrier to the benefits of Motrin 600 mg tablets

The pain-relieving power of *Motrin* 600 mg tablets is welcome at any age. The advantages of *Motrin* become more important as patients grow older.

Advanced age has little or no influence on the pharmacokinetics of *Motrin.*

Motrin is as effective as indomethacin in relieving arthritis pain and inflammation. *Motrin* causes significantly fewer CNS effects and about half as many GI complaints as indomethacin.

Motrin relieves pain as effectively as a combination of aspirin 650 mg plus codeine 60 mg, as documented in analgesia studies.

Motrin has no significant effect on clotting factors in patients on coumarin-type anticoagulants in controlled studies. *Motrin* should be used with caution in persons with intrinsic coagulation defects and in those on anticoagulant therapy.

Motrin is rapidly metabolized and does not accumulate. *Motrin* provides better control of therapy, rapid response to dosage adjustment, and permits tailoring dosage to each patient's needs.



New: The Motrin Patient Brochure
An easy-to-read booklet, provided to physicians, that helps patients understand their arthritis therapy... encourages their cooperation.

Helping you to help your patients—
Ask your Upjohn Representative for a complimentary supply.

The confidence that comes from experience...good reason to prescribe

Motrin® 600 mg TABLETS (ibuprofen)

One tablet t.i.d.

Please turn page for a brief summary of prescribing information.

Upjohn The Upjohn Company
Kalamazoo, Michigan 49001

The Physicians' Champion

In 1975... The medical profession was a punching bag. The "malpractice crisis" staggered doctors with successive blows... more and more lawsuits ...bigger judgments... and, soaring insurance premiums.

But, physicians fought back with the "Spirit of '75."

Round One: They got a new law passed to curb abuses of the legal system.

Round Two: Seven county medical associations and societies formed their own company... SCPIE... Today, the physician policyholders own SCPIE, they run it and they keep any profits.

SCPIE is the physicians' champion... medal winner in their fight for independence. Insuring more Southern California physicians than any other professional liability company. With more real muscle (assets) than any other physician-owned company in the state. Doctors working together to help doctors.

That's the spirit of '75.

scpie

Sponsored by SOCAP

The medical associations and societies of Kern County, Los Angeles County, Orange County, San Bernardino County, San Luis Obispo County, Santa Barbara County, Ventura County.

Before prescribing, see complete prescribing information in SK&F CO. literature or *PDR*. The following is a brief summary.

* **WARNING**

This drug is not indicated for initial therapy of edema or hypertension. Edema or hypertension requires therapy titrated to the individual. If this combination represents the dosage so determined, its use may be more convenient in patient management. Treatment of hypertension and edema is not static, but must be reevaluated as conditions in each patient warrant.

Contraindications: Concomitant use with other potassium-sparing agents such as spironolactone or amiloride. Further use in anuria, progressive renal or hepatic dysfunction, hyperkalemia. Pre-existing elevated serum potassium. Hypersensitivity to either component or other sulfonamide-derived drugs.

Warnings: Do not use potassium supplements, dietary or otherwise, unless hypokalemia develops or dietary intake of potassium is markedly impaired. If supplementary potassium is needed, potassium tablets should not be used. Hyperkalemia can occur, and has been associated with cardiac irregularities. It is more likely in the severely ill, with urine volume less than one liter/day, the elderly and diabetics with suspected or confirmed renal insufficiency. Periodically, serum K^+ levels should be determined. If hyperkalemia develops, substitute a thiazide alone, restrict K^+ intake. **Associated widened QRS complex or arrhythmia requires prompt additional therapy.** Thiazides cross the placental barrier and appear in cord blood. Use in pregnancy requires weighing anticipated benefits against possible hazards, including fetal or neonatal jaundice, thrombocytopenia, other adverse reactions seen in adults. Thiazides appear and triamterene may appear in breast milk. If their use is essential, the patient should stop nursing. Adequate information on use in children is not available. Sensitivity reactions may occur in patients with or without a history of allergy or bronchial asthma. Possible exacerbation or activation of systemic lupus erythematosus has been reported with thiazide diuretics.

Precautions: Do periodic serum electrolyte determinations (particularly important in patients vomiting excessively or receiving parenteral fluids, and during concurrent use with amphotericin B or corticosteroids or corticotropin [ACTH]). Periodic BUN and serum creatinine determinations should be made, especially in the elderly, diabetics or those with suspected or confirmed renal insufficiency. Cumulative effects of the drug may develop in patients with impaired renal function. Thiazides should be used with caution in patients with impaired hepatic function. They can precipitate coma in patients with severe liver disease. Observe regularly for possible blood dyscrasias, liver damage, other idiosyncratic reactions. Blood dyscrasias have been reported in patients receiving triamterene, and leukopenia, thrombocytopenia, agranulocytosis, and aplastic and hemolytic anemia have been reported with thiazides. Thiazides may cause manifestation of latent diabetes mellitus. The effects of oral anticoagulants may be decreased when used concurrently with hydrochlorothiazide; dosage adjustments may be necessary. Clinically insignificant reductions in arterial responsiveness to norepinephrine have been reported. Thiazides have also been shown to increase the paralyzing effect of nondepolarizing muscle relaxants such as tubocurarine. Triamterene is a weak folic acid antagonist. Do periodic blood studies in cirrhotics with splenomegaly. Antihypertensive effects may be enhanced in post-sympathectomy patients. Use cautiously in surgical patients. Triamterene has been found in renal stones in association with the other usual calculus components. Therefore, 'Dyazide' should be used with caution in patients with histories of stone formation. A few occurrences of acute renal failure have been reported in patients on 'Dyazide' when treated with indomethacin. Therefore, caution is advised in administering nonsteroidal anti-inflammatory agents with 'Dyazide'. The following may occur: transient elevated BUN or creatinine or both, hyperglycemia and glycosuria (diabetic insulin requirements may be altered), hyperuricemia and gout, digitalis intoxication (in hypokalemia), decreasing alkali reserve with possible metabolic acidosis. 'Dyazide' interferes with fluorescent measurement of quinidine. Hypokalemia is uncommon with 'Dyazide', but should it develop, corrective measures should be taken such as potassium supplementation or increased dietary intake of potassium-rich foods. Corrective measures should be instituted cautiously and serum potassium levels determined. Discontinue corrective measures and 'Dyazide' should laboratory values reveal elevated serum potassium. Chloride deficit may occur as well as dilutional hyponatremia. Concurrent use with chlorpropamide may increase the risk of severe hyponatremia. Serum PBI levels may decrease without signs of thyroid disturbance. Calcium excretion is decreased by thiazides. 'Dyazide' should be withdrawn before conducting tests for parathyroid function.

Thiazides may add to or potentiate the action of other antihypertensive drugs.

Diuretics reduce renal clearance of lithium and increase the risk of lithium toxicity.

Adverse Reactions: Muscle cramps, weakness, dizziness, headache, dry mouth; anaphylaxis, rash, urticaria, photosensitivity, purpura, other dermatological conditions; nausea and vomiting, diarrhea, constipation, other gastrointestinal disturbances; postural hypotension (may be aggravated by alcohol, barbiturates, or narcotics). Necrotizing vasculitis, paresthesias, icterus, pancreatitis, xanthopsia and respiratory distress including pneumonitis and pulmonary edema, transient blurred vision, sialadenitis, and vertigo have occurred with thiazides alone. Triamterene has been found in renal stones in association with other usual calculus components. Rare incidents of acute interstitial nephritis have been reported. Impotence has been reported in a few patients on 'Dyazide', although a causal relationship has not been established.

Supplied: 'Dyazide' is supplied as a maroon and white capsule, in bottles of 1000 capsules; Single Unit Packages (unit-dose) of 100 (intended for institutional use only); in Patient-Pak™ unit-of-use bottles of 100.

The unique red and white Dyazide® capsule: Your assurance of SK&F quality.

a product of

SK&F CO.

Carolina, P.R. 00630

Like how to find some free time. Or how to keep your spouse happy and your practice flourishing.

We all recognize that practicing good medicine isn't quite good enough these days.

Not if you want to enjoy all the personal satisfactions and rewards that you've trained so hard and worked so long to attain.

That's why the California Medical Association, the Los Angeles County Medical Association and Conomikes Associates are co-sponsoring the Medical Management Conference and Exposition.

It's a first-of-its-kind event that recognizes that you, as a modern physician, have an office to operate, a staff to supervise, records to maintain, billing procedures to manage — all while keeping a close eye on the bottom line.

In other words, you're not only a doctor but a manager and a business executive as well.

At Medical Management, you'll be able to choose from dozens of seminars covering all key aspects of managing your medical practice — the hows and whys of computerized office equipment. . . financial management. . . and the new aspects of third-party payment systems. All relevant. All pertinent to your practice.

Seminars taught by top medical management experts will discuss office procedures, word processing, the legal aspects of medicine, time management, personnel supervision and dozens of other subjects that relate directly to your profitability.

You're invited to stroll the aisles of the exhibit hall. Examine hundreds of time-saving, money-saving products and equipment. Get involved. Ask questions. Discover how the new advances in office technology and medical management systems give you more free time and more efficiency.

Send for an advance copy of the seminar brochure. Mark your calendar and plan to attend this exceptional program designed to respond to many of the business concerns you face as a physician.

MEDICAL MANAGEMENT CONFERENCE AND EXPOSITION
NOVEMBER 16-17, 1984 LOS ANGELES MARRIOTT

☐ Please send me an advance copy of the seminar program, listing all sessions and exhibit hall hours, as soon as it is available.

☐ I may be interested in exhibiting. Please send me full details.

Name _____

Firm _____

Address _____

City _____ State _____ Zip _____

Phone _____
Area Code Extension

Please send to: MEDICAL MANAGEMENT
CONFERENCE AND EXPOSITION
c/o Expocon Management Associates
3695 Post Road, Southport, CT 06490

Things they never taught in med school

MEDICAL MANAGEMENT
CONFERENCE AND EXPOSITION
NOVEMBER 16-17, 1984 LOS ANGELES MARRIOTT

SPONSORED BY:
CALIFORNIA MEDICAL ASSOCIATION
LOS ANGELES COUNTY MEDICAL ASSOCIATION
CONOMIKES ASSOCIATES

Classified Advertisements

The rate for each insertion is **$5 per line** (average six words per line) **with five line ($25) minimum.** Box number charge: $5 each month.

Classified display rates $50 per inch.

Copy for classified advertisements should be received not later than **the first of the month preceding issue. All copy must be typed or printed.** • Classified advertisers using Box Numbers forbid the disclosure of their identity. Your inquiries in writing will be forwarded to Box Number advertisers. The right is reserved to reject or modify all classified advertising copy in conformity with the decisions of the Advertising Committee.

Please Type or Print Advertising Copy

Classified Advertisements Are Payable in Advance

THE WESTERN JOURNAL OF MEDICINE
44 GOUGH STREET, SAN FRANCISCO, CA 94103

PHYSICIANS WANTED

GENERAL INTERNIST, Board certified/eligible: Multi-specialty group, university town central Washington, has space and services available on a lease or compensation basis with future partnership anticipated. Contact A. J. Grose, MD, Medical Building Associates, P.O. Box 369, Ellensburg, WA 98926.

CALIFORNIA—URGENT CARE. Positions available for Summer 1984 in free-standing, urgent care settings in several locations. Board certification or eligibility in emergency medicine, family practice or related specialty required. Opportunities exist for directorships for physicians with appropriate experience. Guaranteed minimum, malpractice paid, benefit package available. Contact: California Emergency Physicians, 440 Grand Avenue, Suite 500, Oakland, CA 94610, (415) 832-6400.

ENDOCRINOLOGIST: Immediate opening in private practice. Exclusively subspecialty: Endo/Diabetes. Los Angeles. Reply with CV to Box 6421, Western Journal of Medicine, 44 Gough St., San Francisco, CA 94103.

HEALTH OFFICER—Natrona County Board of Health invites applications for County Health Officer. Required MD, eligibility for licensure in Wyoming, MPH degree or five years experience as a paid physician in preventive medicine and environmental health. 70,000 population located in the heart of prime hunting and fishing. Salary $50,000 to $65,000 depending on qualifications and experience. Excellent fringe benefits. Send curriculum vitae by September 1, 1984, to Search Committee, Health Department, 1200 E. 3rd, Casper, WY 82601. EOE

WANTED FAMILY PRACTITIONER(S). Gateway to the Oregon Caves. 15,000 plus residents In lovely valley. Excellent referral system. 29 miles from hospitals. Enjoy the excitement of a rural family practice and time to spend outdoors. Board of Directors anxious to expand to meet community needs. Now available, one-half fully equipped modern clinic. Room for one or two physicians with excellent expansion potential. Expansion could be emergency type care or convalescent home. Call AC (503) 592-3916 or 592-2224 evenings or weekends.

SAN FRANCISCO & SEATTLE: CHEC Medical Centers has practce opportunities for physicians interested in Primary Medicine/Minor Emergency Care. Guaranteed base plus financial incentives, malpractice coverage, health insurance, paid vacation and CME time, and practice equity provided. Please send CV to Richard Miller, Director of Physician Services, CHEC Medical Centers, 2200 6th Avenue, Suite 1200-BB, Seattle, WA 98121.

PHYSICIANS WANTED

Southern California Family Practitioner

Our well established medical group has a few opportunities for Board Certified or Eligible Family Practitioners.

Active inpatient care at nearby hospitals. Fine HMO enrollment as well as private patients and Industrial Medicine.

Excellent remuneration consisting of salary, fee-for-service bonus, HMO bonus, and partnership option.

Call or send CV to:
VERN HOWE
Pacific Physician Services
PO Box 1346
Loma Linda, CA 92354
(714) 825-4401

PEDIATRICIAN—Solo practice in Southeastern New Mexico. Ideal family living in prosperous community serving 85,000. Income guarantee, new office available adjacent to 106-bed JCAH-accredited hospital. Send CV to Dave Templeton, Southwest Community Health Services, Albuquerque, NM 87102, or call 1 (800) 545-4030, extension 3050.

CALIFORNIA: LOS ANGELES/SAN DIEGO. Positions available for ED Physicians, Family Practitioners and qualified Internists for rapidly expanding urgent care facilities. Minimum guarantee $30/hr vs percentage of gross. Paid malpractice. Send CV to: Regional Medical Director, Instant Care Centers of America, 100 Oceangate Ste 524, Long Beach, CA 90802.

PHYSICIANS WANTED

INTERNIST, Board certified or eligible, to join Monterey County, California, 5-physician group, all Board certified. Competence in Intensive Care necessary. Send curriculum vitae to Box 6412, Western Journal of Medicine, 44 Gough St., San Francisco, CA 94103.

ORTHOPEDIC SURGEON—Solo practice In Southwestern New Mexico. Ideal family living in prosperous community serving 85,000. Income guarantee. New office located adjacent to 106-bed, JCAH-accredited hospital. Send CV to Dave Templeton, Southwest Community Health Services, Albuquerque, NM 87102, or call 1 (800) 545-4030, extension 3050.

CARDIOLOGIST: Invasive or non-invasive. Preferably speaks some Spanish. An opportunity to develop testing in a small community hospital and a private practice in California's Imperial Valley. Financial arrangements negotiable (rent subsidy, etc). Reply to Box 6432, Western Journal of Medicine, 44 Gough St., San Francisco, CA 94103.

THE OFFICE OF WORKERS' COMPENSATION PROGRAMS is seeking Board eligible/certified physicians to provide second opinion evaluations. Specialties include Orthopedics, ENT, Psychiatry, Cardiology, and Neurosurgery/Neurology. Locations include the San Francisco Bay Area, the Greater Los Angeles Area, San Diego, and Las Vegas. A contracted second opinion physician is precluded from also providing referee exams and is subject to fee schedule. Please send curriculum vitae to: Gerald T. Cullen, Contracting Officer, Office of Workers' Compensation Programs, US Dept. of Labor, 450 Golden Gate Ave., P.O. Box 36066, San Francisco, CA 94102.

ER PHYSICIAN needed for emergency departmen in small community hospital located on the coast 25 miles south of San Francisco. Reply: Dr Timothy Whelan, St. Catherine's Hospital, Moss Beach, CA 94038.

THE DEPARTMENT OF FAMILY MEDICINE at University of California, Irvine is recruiting for a Spanish-speaking Pediatrician with MPH degree and teaching experience. The appointment will be at the assistant professor level in the clinical series. Send curriculum vitae to: J. Dennis Mull, MD, Chairman, Department of Family Medicine, University of California, Irvine, 101 City Drive South, Orange, CA 92668. An Affirmative Action/Equal Opportunity Employer.

FAMILY PRACTICE PHYSICIANS and Primary Care Internists openings available in rural group practice in Northern California. Full or part time. Very competitive salary and good working conditions Contact (707) 829-0992.

(Continued on Page 144)

ARA services

SPECTRUM EMERGENCY CARE, Inc.

Career emergency medicine positions are available with the nation's largest group in the following states:

California	**Montana**	**S. Dakota**
Colorado	**Nebraska**	**Utah**
Idaho	**Nevada**	**Washington**
Kansas	**N. Dakota**	**Wyoming**

Spectrum provides career emergency physicians with a competitive income; professional liability insurance; and reimbursement of CME tuition, ACEP dues, ACLS and ATLS training. For complete details on positions available in the states listed above contact:

Jan Bird
Spectrum Emergency Care, Inc.
6275 Lehman Drive
Suite C 202
Colorado Springs, CO 80918

1-800-525-3681 / 303-590-1755 / 1-800-421-6655

In clinical anxiety,

Upjohn THE UPJOHN COMPANY
Kalamazoo, Michigan 49001 USA

depressive symptoms are part of the picture in 7 out of 10 geriatrics.

The geriatric profile of XANAX can help.

In a recent clinical study* of 83 geriatric patients with clinical anxiety 73% were diagnosed as also having symptoms of depressed mood.

XANAX is well suited for therapy because it demonstrates greater efficacy than placebo in reducing the overall Hamilton Anxiety Rating Scale Total Score by significantly reducing individual items including depressed mood (see Figure).



A desirable profile of clinical advantages

- **Rapidly relieves** the symptoms of anxiety including depressed mood
- **No clinically significant ECG changes** over the course of therapy
- **Relieves the symptoms of insomnia** significantly better than placebo
- Drowsiness is the most frequently reported adverse effect
- **Simple geriatric dosage**—0.25 mg two or three times daily

Xanax® 0.25 mg Tablets

Ⓒ IV

(Continued from Page 139)

BOARD CERTIFIED Oncologist, Cardiologist, Internist, Neurosurgeon, Otorhinolaryngologist for Southeastern Washington—Tri-Cities, 150,000 population. Outdoor activities abound. Group or solo opportunities. Contact Vesta Skiens, Kennewick General Hospital (509) 586-6111 (309).

INTERNIST, CALIFORNIA, two American trained, Board certified General Internists seek the same for association in busy practice in Central San Joaquin Valley city of 50,000. No investment required. Subspecialist with interest in doing some general Internal Medicine desirable. Excellent recreational area with access to San Francisco, Yosemite and coast. Opportunity to establish a busy independent practice with no initial investment. Reply to: Box 6434, Western Journal of Medicine, 44 Gough St., San Francisco, CA 94103.

GENERAL SURGEON, Board certified/eligible: multispecialty group, university town central Washington, has space and services available on a lease or compensation basis with future partnership anticipated. Contact J. W. Devney, MD, Medical Building Associates, P.O. Box 369, Ellensburg, WA 98926.

DERMATOLOGIST WANTED. Southern California. Board certified or eligible for permanent part-time two to three days weekly. Salary negotiable. Reply with CV to Box 6429, Western Journal of Medicine, 44 Gough St., San Francisco, CA 94103.

OBSTETRICIAN GYNECOLOGIST—Board certified or eligible—to join multispecialty group. Hospital facilities adjacent. Gateway to San Juan Islands. Excellent recreational opportunities. Send CV to: Dr Harold Clure, Family and Internal Medicine Associates, 24th & M Avenue, Anacortes, WA 98221, or call (206) 293-3101.

F/T OB/GYN for growing multispecialty group in sunny L.A. Spanish very important. 1st year compensation negotiable. Partnership potential 2nd year. CV to Med. Dir. Box 6435, Western Journal of Medicine, 44 Gough St., San Francisco, CA 94103.

EXCELLENT OPPORTUNITY FOR BOARD CERTIFIED INTERNIST. Position available imediately in well-established practice—owner retiring. Flexible arrangements. Beautiful recreation area. CV with reply to: Welty & Welty, W. 407 Riverside, #1680, Spokane, WA 99201.

CALIFORNIA LICENSED PHYSICIAN needed to perform brief physical exams. Areas San Jose/South Bay Area. Call Ricci (213) 272-0171 or 1 (800) MEDS-4-XAM.

EXCELLENT OPPORTUNITY FOR ORTHOPEDIST to join a 35 member multi-specialty group practice located in one of the finest oceanside communities in Southern California. Excellent compensation program based on guarantee plus incentive. Send CV or call: Marc Moser, Administrator, Redondo Beach Medical Group, 502 Torrance Boulevard, Redondo Beach, CA 90277; (213) 316-0811, ext. 614.

NEUROSURGEON—Southeastern New Mexico. To establish new practice in growing community serving 85,000. New 106-bed hospital, JCAH-accredited. Has newly operational CAT. Income guarantee. New office available adjacent to hospital. Send CV to Dave Templeton, Southwest Community Health Services, Albuquerque, NM 87102, or call 1 (800) 545-4030, extension 3050.

NORTHERN CALIFORNIA: Physician, Board certified/qualified in Emergency Medicine or Family Practice, to work 16-32 hours per week in a busy freestanding emergency center. Prefer someone interested in full-time position within 3-6 months. Competitive compensation, malpractice, and bonus for part-time position. Full-time position will also include health insurance, vacation, educational expenses and other benefits. Send CV and references to Joanne Berkowitz, MD, The Emergency Center Medical Group, 4948 San Juan Avenue, Fair Oaks, CA 95628.

GENERAL/FAMILY PRACTICE

CIGNA Healthplans of California is offering a career opportunity to General and Family Practitioners with acute and preventive medicine orientation. Our HMO provides a personal patient population and a continuity of care as well as an excellent compensation package. Send curriculum vitae to:

Director Physician Recruitment

CIGNA Healthplans of California

700 N. Brand Blvd, Ste. 500
Glendale, CA 91203

Equal Opportunity Employer

FAMILY PRACTICE—NORTH IDAHO: ABFP or eligible to join low-key, but busy practice, excellent and beautiful family area. Lab, x-ray on premises, 24 hour ER coverage. Terms negotiable. Call (208) 773-1577 or respond with CV to 2209 Canyon Dr, Coeur d'Alene, ID 83814.

WASHINGTON: Expanding physician-owned emergency group has opening for full-time career-oriented Emergency Physicians in south central Washington. Excellent benefitss including malpractice, disability, health insurance, profit sharing, etc. Flexible work schedules, excellent working and living conditions. Contact Donald Kougl, MD, (307) 234-4795, or send CV to EMP, P.C., PO Box 3398, Casper, WY 82602-3398.

SOUTH DAKOTA: Expanding physician-owned emergency group has opening for full-time career-oriented Emergency Physicians in South Dakota. Excellent benefits including malpractice, disability, health insurance, profit sharing, etc. Flexible work schedules, excellent working and living conditions. Contact Donald Kougl, MD, (307) 234-4795, or send CV to EMP, P.C., PO Box 3398, Casper, WY 82602-3398.

GENERAL PRACTITIONERS—Specialists—Full-time positions or Locum Tenens. If you're considering a change—let's talk. We have opportunities in California and other West Coast areas. Send your CV to: Physician Search Associates Agency Inc., 1835 Orangewood Ave., Suite 306, Orange, CA 92668.

CLINICAS DEL CAMINO REAL, INC. is seeking two Family Practice Physicians to augment its medical practice. Pay range is $4,200 to $4,700 per month plus 3 weeks vacation, sick leave, tax deferred plan, holidays and an excellent working environment located in Ventura County. Send résumé to Robert S. Juarez, Executive Director, PO Box 4878, Ventura, CA 93004. Bilingual Spanish/English desirable. An EOE.

OCCUPATIONAL MEDICINE PHYSICIAN: Santa Barbara County Health Care Services. Full-time position. Board certified/eligible Occupational Medicine. Clinical and Administrative responsibilities. Send CV to: Gary Erbeck, MPH, Santa Barbara County Health Care Services, 315 Camino del Remedio, Santa Barbara, CA 93110.

RADIOLOGIST—Board eligible or certified, well versed in General Radiology, Realtime Ultrasound, Nuclear Medicine and CT. Excellent growth and future in active office and hospital practice—Contact (209) 222-3357. Temporary locum tenens considered.

POSITION AVAILABLE IN GENERAL INTERNAL MEDICINE. Community offers ideal family living in town of 12,000 people. Liberal fringe benefits—life insurance, health insurance, 30 days vacation plus 15 days sick leave each year. Complete malpractice insurance coverage provided. An unexcelled opportunity to engage in a challenging medical practice in a rural setting offering unlimited recreational opportunities —hunting, fishing, skiing, plus fresh clean air in abundance. Contact: P. J. Shannon, Chief, Personnel Service, VA Medical Center, Miles City, MT 59301. Telephone: (406) 232-3060, ext.. 201. An Equal Opportunity Employer.

ASSISTANT HEALTH OFFICER—Director of Preventive Medical Services, San Joaquin Local Health District, serving county-wide population of 390,000. Requires: California license; MPH and/or Board qualified in Preventive Medicine, Pediatrics, or Internal Medicine; two years experience in public health. Salary $4,571-$5,555/month, negotiable. Call or write Jack J. Williams, MD, District Health Officer, San Joaquin Local Health District, PO Box 2009, Stockton, CA 95201 (209) 466-6781. Equal Employment Opportunity Employer.

GENERAL SURGEON, SUN VALLEY, IDAHO. Energetic general surgeon to practice with multi-specialty group. Well equipped adjacent hospital. Quality of life high, income moderate. Curriculum vitae and references with first letter please. Dr Lynn T. Levy, PO Box 66, Sun Valley, ID 83353.

OB-GYN—MAUI, HAWAII. Good opportunity to establish enjoyable practice. Write John Withers, MD, 53 Puunene Avenue, Kahului, Maui, HA 96732 or call (808) 877-6655.

PHYSICIAN-GP to join 2 office practice in San Francisco. Build to F/T. Teaching and research opportunity also combining East/West approaches. Letter and CV to Director, 2409 19th Avenue, San Francisco, CA 94116.

DIAGNOSTIC RADIOLOGIST desires situation in small hospital (25-50 beds) CT and Ultrasound (real time). Willing to do some locums. Licensed in California, Oregon and Washington. Please reply Box 6436, Western Journal of Medicine, 44 Gough St., San Francisco, CA 94103.

THIRD-YEAR RESIDENT in Diagnostic Radiology seeks locum tenens work in same. Willing to travel. Many substantial references. PO Box 620578, Woodside, CA 94062.

LOCUM TENENS SERVICE

WESTERN PHYSICIANS REGISTRY

. . . offers coverage for vacation or continuing education. To arrange coverage for your practice or to participate as temporary physician, contact: **Carol Sweig, Director, 1124 Ballena, Alameda, CA 94501; (415) 521-4110.**

A MEDICAL LETTER INCREASES PATIENT VISITS! Write Shirley M. Mueller, MD, for a free copy of a Physician-written newsletter that is personalized by you. Personal Medical Communications, Dept. D, 95 Wellington Road, Indianapolis, IN 46260.

CASH AVAILABLE

Doctors . . . we will buy your used equipment and lease it back. You get cash with tax deductible payments.

Free details contact:

LaMONTE FINANCIAL MANAGEMENT
(213) 839-2778

CALIFORNIA AND WESTERN STATES. HIGH INCOME practices for sale: Ophthalmology, Orthopedics, Endocrinology, Radiology, OB/GYN, Psychiatry, Internal, Family, Pediatric, Surgery, others. Mary Bradshaw, Professional Practice Opportunities, 21 Altamount Drive, Orinda, CA 94563; (415) 376-0762. Sales, Appraisals, Consulting, Placement, Résumé preparation service.

(Continued on Page 146)

(Continued from Page 144)

FAMILY PRACTICE. Physician retiring. Fully equipped office, exam rooms, x-ray, full lab and surgery. Beautiful San Diego—Close to all. Contact Harold Peterson, MD, (619) 582-8181 or 440-2740.

FAMILY PRACTICE—Several locations within New Mexico. These are private-practice opportunities with income guarantee. Send CV to Dave Templeton, Southwest Community Health Services, Aubuquerque, NM 87102 or call 1 (800) 545-4030, extension 3050.

PROFESSIONAL PRACTICE SERVICES—Specializing in the sale and appraisal of practices in Sacramento and surrounding Northern Calif. areas. 884 Lincoln Way, Ste. 38, Auburn, CA 95603; (916) 823-2340.

UTAH—ASSUME ESTABLISHED FAMILY PRACTICE mins. from 2 universities and ski slopes, 5 miles from hospital with all specialties. Fully equipped office includes x-ray. Purchase equipment, rent office. No charge for practice. Box 103, Lehi, UT 84043.

ORTHOPAEDIC PRACTICE, ORANGE, COUNTY, CALIFORNIA, adjacent to major hospital, five additional hospitals in 5-mile radius, will aid in transition. Box 4191, Irvine, CA 92714.

ALLERGY, SAN FRANCISCO BAY area. Seller plans to retire at end of 1984. 85% of practice concerns environmentally induced illnesses, 15% Forensic Medicine. Buyer must be Board certified in Allergy and Immunology or Toxicology and have extensive post graduate training and experience in clinical ecology. Strong research and academic background essential. Income has averaged 450-K over the past 5 years. Easy terms. For further information please write Box 6437, Western Jounal of Medicine, 44 Gough St., San Francisco, CA 94103.

MONTANA—Pogressive 30 physician multispecialty group has outstanding practice opportunities for the following specialties: Allergy, Endocrinology, Infectious Disease, Gastroenterology, Otolaryngology, Psychiatry and Orthopaedic Surgery. For further information, contact Wyman Taylor, Administrator, Great Falls Clinic, PO Box 5012, Great Falls, MT 59405 or (406) 454-2171.

OB/GYN, SAN DIEGO. Grossing $400K/Yr with high net. Long estab. Beautiful, large office, adj. to hosp. Very few deliveries. The Oak Tree Associates, 2030 E. 4th Street, #253, Santa Ana, C9 92705. (714) 541-2600, (213) 201-0122.

MEDICAL OFFICE SPACE available for lease. 1,075 sq ft in Berkeley near Alta Bates. Please call The Berkeley Central Medical Building at (415) 848-5137.

PUBLIC HEALTH PHYSICIAN

The California Department of Health Services is recruiting physicians. Openings in Sacramento and Berkeley which exist or/are anticipated over the next two years in the following areas: general infectious disease, venereal disease, cancer control and epidemiology, nosocomial infections, maternal and child health, occupational health, public health administration, medical toxicology, environmental epidemiology (air and water pollution), general chronic diseases, behavioral epidemiology/violence. Civil Service Examinations will be conducted in early September 1984 for the categories of Public Health Medical Officer (PHMO) II, PHMO III, PHMO III-Epidemiology. Telephone interviews are possible. California licensure is required prior to hiring but only licensure eligibility is needed to compete in the examination. Annual salary starts at $49,872 for the PHMO II, and $54,852 for the PHMO III and PHMO III-Epi. You are urged to apply before August 31, 1984.

Résumés should be sent to:

Robin Kubochi
Department of Health Services
Health Protection Division
714 P Street
Sacramento, California 95814

Upon receipt of résumé, further information will be provided. The State Department of Health Services is an equal opportunity employer.

MEDICAL OFFICE PLAZA. New building in Castro Valley next to Laurel Grove and Eden Hospitals. Space and size designed to your specifications, utilities included. Option to purchase. TCT Investments. (415) 889-2950.

OFFICE SPACE AVAILABLE
Castro Valley, California
THE GROVE WAY MEDICAL CENTER
800 to 1,600 sq. ft. Suites. Some set-up for two-man or group practices. FULLY SERVICED building, Pharmacy, Lab and X-ray on premises. $1.00 sq. ft.
Call 428-0823 or 932-5197

OFFICE SUITE designed for Ophthalmology practice, 1,308 sq ft, full service medical bldg. Generous allowance for redecorating. Located in fastest growing community in California. Call Anna Bischof (805) 485-3193, A Martin V. Smith Development, Oxnard, California.

OFFICE SPACE—Available in well established, diversified medical-dental-pharmacy building. Good San Francisco Bay Area location in Pleasant Hill. Easy access to freeway. Ownership an option. For more information call (415) 689-4404 or (415) 676-8485.

OFFICE SUITES FOR LEASE. 800-1,400 sq ft. Establish your practice in fast growing Oxnard, Ventura County, California. Full service bldg. Desire specialties: Nephrology, Int. Med., Ortho-Surgeon, etc. Contact Anna Bischof (805) 485-3193.

MEDICAL PRACTICES - BUYING or SELLING

WANTED - GENERAL, IND. MED., ALL SPECIALTY PRACTICES

897-OB/GYN	West L.A.	Gr. $330K
895-G.P.-LOCATION	Ventura County	
891-GENERAL PRACTICE	High Desert	Gr. $ 95K
883-GENERAL PRACTICE	Orange County	Gr. $125K
882-G.P.-R.E. AVAIL.	Riverside County	Gr. $320K
879-G.P./SURGEON	Missouri	Gr. $375K
867-G.P./CLINIC/R.E.	L.A. County	Gr. $350K
873-G.P. + R.E.	L.A. County	Gr. $250K+
852-OPHTHALMOLOGY	Los Angeles	Gr. $224K
861-INT./ONCOLOGY	Long Beach area	Gr. $250K+
886-G.P./PREV.MED.	Santa Barbara County	Gr. $110K
893-INTERNAL MED.	West L.A.	Gr. $230K
889-INT. MED./EMERGENCY	West L.A.	Gr. $890K

PPS **Professional Practice Sales**
Serving the professions since 1966
Nationwide services

SO. CALIFORNIA 364 E. First St., Tustin, CA 92680 (714) 832-0230
NO. CALIFORNIA 1428 Irving St., San Francisco, CA 94122 (415) 661-0700

REDONDO BEACH
LOS ANGELES COUNTY

Free standing Medical Building located in a prime residential and condominium area, close to three hospitals, and to the beach. Has been a medical office for over 30 years. 2,000 sq ft, many glass windows, lanai and patio. Ideal for one or two doctors and very suitable for time and day sharing especially for Pediatricians, Psychiatrists, GP/FPs, or other desiring idyllic surroundings for their patients instead of stone walls and forced air ventilation. Must be seen to be appreciated.

For full details, CONTACT:

William Bailey, MD
in care of Mr St. Clair
4001 Pacific Coast Highway, Suite 112
Torrance, CA 90505
PHONE: (213) 373-8896

Improving the outlook... in mixed depression and anxiety

A rational approach, combining

- The standard antidepressant: amitriptyline
- The proven anxiolytic: Librium® (chlordiazepoxide HCl/Roche)Ⓥ

Marked improvement often occurs as early as the first week.

Headache, insomnia or GI upsets associated with mixed depression and anxiety often respond quickly.

Feeling better, patients feel encouraged to stay the course—therefore, fewer dropouts due to side effects: $p < 0.006$ compared to amitriptyline.* Patients should be cautioned about the combined effects of Limbitrol with alcohol and other CNS depressants, and about activities requiring complete mental alertness such as operating machinery or driving a car.

*Feighner JP: *Psychopharmacology* 61:217-225, Mar 22, 1979.

A Roche Medication Education Booklet—

"You, your medical problem and your treatment with Limbitrol."

Valuable adjunct to dual therapy with Limbitrol:

Because an informed patient is more responsive...

This easy-to-read brochure explains the rationale of dual therapy with Limbitrol and encourages patient compliance. To obtain a complimentary supply, please contact your Roche representative.

In moderate depression and anxiety

Limbitrol®Ⓥ

Tablets 5-12.5 each containing 5 mg chlordiazepoxide and 12.5 mg amitriptyline (as the hydrochloride salt)

Tablets 10-25 each containing 10 mg chlordiazepoxide and 25 mg amitriptyline (as the hydrochloride salt)

Rapid clearing through dual action

LIMBITROL® Tablets Ⓥ
Tranquilizer-Antidepressant

Before prescribing, please consult complete product information, a summary of which follows:

Indications: Relief of moderate to severe depression associated with moderate to severe anxiety.

Contraindications: Known hypersensitivity to benzodiazepines or tricyclic antidepressants. Do not use with monoamine oxidase (MAO) inhibitors or within 14 days following discontinuation of MAO inhibitors since hyperpyretic crises, severe convulsions and deaths have occurred with concomitant use; then initiate cautiously, gradually increasing dosage until optimal response is achieved. Contraindicated during acute recovery phase following myocardial infarction.

Warnings: Use with great care in patients with history of urinary retention or angle-closure glaucoma. Severe constipation may occur in patients taking tricyclic antidepressants and anticholinergic-type drugs. Closely supervise cardiovascular patients. (Arrhythmias, sinus tachycardia and prolongation of conduction time reported with use of tricyclic antidepressants, especially high doses. Myocardial infarction and stroke reported with use of this class of drugs.) Caution patients about possible combined effects with alcohol and other CNS depressants and against hazardous occupations requiring complete mental alertness (e.g., operating machinery, driving).

***Usage in Pregnancy:* Use of minor tranquilizers during the first trimester should almost always be avoided because of increased risk of congenital malformations as suggested in several studies. Consider possibility of pregnancy when instituting therapy; advise patients to discuss therapy if they intend to or do become pregnant.**

Since physical and psychological dependence to chlordiazepoxide have been reported rarely, use caution in administering Limbitrol to addiction-prone individuals or those who might increase dosage; withdrawal symptoms following discontinuation of either component alone have been reported (nausea, headache and malaise for amitriptyline; symptoms [including convulsions] similar to those of barbiturate withdrawal for chlordiazepoxide).

Precautions: Use with caution in patients with a history of seizures, in hyperthyroid patients or those on thyroid medication, and in patients with impaired renal or hepatic function. Because of the possibility of suicide in depressed patients, do not permit easy access to large quantities in these patients. Periodic liver function tests and blood counts are recommended during prolonged treatment. Amitriptyline component may block action of guanethidine or similar antihypertensives. Concomitant use with other psychotropic drugs has not been evaluated; sedative effects may be additive. Discontinue several days before surgery. Limit concomitant administration of ECT to essential treatment. See Warnings for precautions about pregnancy. Limbitrol should not be taken during the nursing period. Not recommended in children under 12. In the elderly and debilitated, limit to smallest effective dosage to preclude ataxia, oversedation, confusion or anticholinergic effects.

Adverse Reactions: Most frequently reported are those associated with either component alone: drowsiness, dry mouth, constipation, blurred vision, dizziness and bloating. Less frequently occurring reactions include vivid dreams, impotence, tremor, confusion and nasal congestion. Many depressive symptoms including anorexia, fatigue, weakness, restlessness and lethargy have been reported as side effects of both Limbitrol and amitriptyline. Granulocytopenia, jaundice and hepatic dysfunction have been observed rarely.

The following list includes adverse reactions not reported with Limbitrol but requiring consideration because they have been reported with one or both components or closely related drugs.

Cardiovascular: Hypotension, hypertension, tachycardia, palpitations, myocardial infarction, arrhythmias, heart block, stroke.

Psychiatric: Euphoria, apprehension, poor concentration, delusions, hallucinations, hypomania and increased or decreased libido.

Neurologic: Incoordination, ataxia, numbness, tingling and paresthesias of the extremities, extrapyramidal symptoms, syncope, changes in EEG patterns.

Anticholinergic: Disturbance of accommodation, paralytic ileus, urinary retention, dilatation of urinary tract.

Allergic: Skin rash, urticaria, photosensitization, edema of face and tongue, pruritus.

Hematologic: Bone marrow depression including agranulocytosis, eosinophilia, purpura, thrombocytopenia.

Gastrointestinal: Nausea, epigastric distress, vomiting, anorexia, stomatitis, peculiar taste, diarrhea, black tongue.

Endocrine: Testicular swelling and gynecomastia in the male; breast enlargement, galactorrhea and minor menstrual irregularities in the female; elevation and lowering of blood sugar levels; and syndrome of inappropriate ADH (antidiuretic hormone) secretion.

Other: Headache, weight gain or loss, increased perspiration, urinary frequency, mydriasis, jaundice, alopecia, parotid swelling.

Overdosage: Immediately hospitalize patient suspected of having taken an overdose. Treatment is symptomatic and supportive. I.V. administration of 1 to 3 mg physostigmine salicylate has been reported to reverse the symptoms of amitriptyline poisoning. See complete product information for manifestation and treatment.

Dosage: Individualize according to symptom severity and patient response. Reduce to smallest effective dosage when satisfactory response is obtained. Larger portion of daily dose may be taken at bedtime. Single *h.s.* dose may suffice for some patients. Lower dosages are recommended for the elderly.

Limbitrol 10-25: initial dosage of three or four tablets daily in divided doses; increased up to six tablets or decreased to two tablets daily as required. Limbitrol 5-12.5: initial dosage of three or four tablets daily in divided doses; for patients who do not tolerate higher doses.

How Supplied: White, film-coated tablets, each containing 10 mg chlordiazepoxide and 25 mg amitriptyline (as the hydrochloride salt) and blue, film-coated tablets, each containing 5 mg chlordiazepoxide and 12.5 mg amitriptyline (as the hydrochloride salt)—bottles of 100 and 500; Tel-E-Dose® packages of 100; Prescription Paks of 50.

ROCHE®
ROCHE PRODUCTS INC
Manati, Puerto Rico 00701



ROCHE

Limbitrol®

Each tablet contains 5 mg chlordiazepoxide and 12.5 mg amitriptyline

5 mg chlordiazepoxide and 25 mg amitriptyline